WO1995009913A9 - Human monocyte/macrophage derived metalloproteinase inhibitor - Google Patents
Human monocyte/macrophage derived metalloproteinase inhibitorInfo
- Publication number
- WO1995009913A9 WO1995009913A9 PCT/US1994/011599 US9411599W WO9509913A9 WO 1995009913 A9 WO1995009913 A9 WO 1995009913A9 US 9411599 W US9411599 W US 9411599W WO 9509913 A9 WO9509913 A9 WO 9509913A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- timp
- cells
- sequence
- dna
- human
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 title abstract description 61
- 210000002540 Macrophages Anatomy 0.000 title abstract description 38
- 210000001616 Monocytes Anatomy 0.000 title abstract description 37
- 101700047914 FETAF Proteins 0.000 title description 3
- 101700012346 FTE46 Proteins 0.000 title description 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 title description 3
- 101710004645 smpI Proteins 0.000 title description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims abstract description 201
- 229920001850 Nucleic acid sequence Polymers 0.000 claims abstract description 46
- 108090001123 antibodies Proteins 0.000 claims abstract description 34
- 102000004965 antibodies Human genes 0.000 claims abstract description 34
- 230000014509 gene expression Effects 0.000 claims abstract description 32
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 14
- 108020004511 Recombinant DNA Proteins 0.000 claims description 8
- 230000000875 corresponding Effects 0.000 claims description 7
- 206010003246 Arthritis Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 4
- 108020004491 Antisense DNA Proteins 0.000 claims description 3
- 239000003816 antisense DNA Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 201000008838 periodontal disease Diseases 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000023 polynucleotide Polymers 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 210000004027 cells Anatomy 0.000 abstract description 81
- 238000009396 hybridization Methods 0.000 abstract description 23
- 230000027455 binding Effects 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 3
- 102100006015 TIMP3 Human genes 0.000 description 185
- 235000018102 proteins Nutrition 0.000 description 56
- 102000004169 proteins and genes Human genes 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 56
- 229920002676 Complementary DNA Polymers 0.000 description 39
- 238000000034 method Methods 0.000 description 39
- 239000002299 complementary DNA Substances 0.000 description 37
- 102100002607 TIMP1 Human genes 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 22
- 210000001519 tissues Anatomy 0.000 description 22
- 102000005741 Metalloproteases Human genes 0.000 description 18
- 108010006035 Metalloproteases Proteins 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 15
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 15
- 229940014598 TAC Drugs 0.000 description 13
- 230000002759 chromosomal Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 210000000349 Chromosomes Anatomy 0.000 description 11
- 101700040544 TIMP1 Proteins 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 229920000272 Oligonucleotide Polymers 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 230000002068 genetic Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 210000002744 Extracellular Matrix Anatomy 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000001580 bacterial Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 7
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 6
- 210000004408 Hybridomas Anatomy 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108010045030 monoclonal antibodies Proteins 0.000 description 6
- 102000005614 monoclonal antibodies Human genes 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 210000000988 Bone and Bones Anatomy 0.000 description 5
- 108090000745 Immune Sera Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000975 bioactive Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108091007521 restriction endonucleases Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 102000018358 Immunoglobulins Human genes 0.000 description 4
- 108060003951 Immunoglobulins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003636 conditioned culture media Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000001605 fetal Effects 0.000 description 4
- 230000037320 fibronectin Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- 230000000242 pagocytic Effects 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000020504 Collagenase family Human genes 0.000 description 3
- 108060005980 Collagenase family Proteins 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- 108010013563 Lipoprotein lipase Proteins 0.000 description 3
- 102000017055 Lipoprotein lipase Human genes 0.000 description 3
- 102100018200 MMP1 Human genes 0.000 description 3
- 102100006844 MMP9 Human genes 0.000 description 3
- 210000004379 Membranes Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001672 Ovary Anatomy 0.000 description 3
- 102000035443 Peptidases Human genes 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 101700045331 TIMP3 Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000000692 anti-sense Effects 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037240 fusion proteins Human genes 0.000 description 3
- 201000002406 genetic disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002797 proteolythic Effects 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000004881 tumor cells Anatomy 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 2
- JQDFGZKKXBEANU-UHFFFAOYSA-N Alanyl-Cysteine Chemical compound CC(N)C(=O)NC(CS)C(O)=O JQDFGZKKXBEANU-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- OMSMPWHEGLNQOD-UHFFFAOYSA-N Asparaginyl-Phenylalanine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UHFFFAOYSA-N 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 210000003917 Chromosomes, Human Anatomy 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 102000015612 Complement 3b Receptors Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 210000000805 Cytoplasm Anatomy 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 210000002458 Fetal Heart Anatomy 0.000 description 2
- 210000003754 Fetus Anatomy 0.000 description 2
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 210000004754 Hybrid Cells Anatomy 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 2
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 2
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 2
- 102100014894 MMP2 Human genes 0.000 description 2
- 101700060512 MMP2 Proteins 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 210000003003 Monocyte-Macrophage Precursor Cells Anatomy 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 210000002997 Osteoclasts Anatomy 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 210000002826 Placenta Anatomy 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010078762 Protein Precursors Proteins 0.000 description 2
- 102000014961 Protein Precursors Human genes 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108050000761 Serpin family Proteins 0.000 description 2
- 102000008847 Serpin family Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- MFEVVAXTBZELLL-UHFFFAOYSA-N Tyrosyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-UHFFFAOYSA-N 0.000 description 2
- -1 Zn++ cation Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 239000002787 antisense oligonuctleotide Substances 0.000 description 2
- 230000003143 atherosclerotic Effects 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 108020004256 beta-Lactamases Proteins 0.000 description 2
- 102000006635 beta-Lactamases Human genes 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003413 degradative Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002148 osteoclast Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001177 retroviral Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000000717 tumor promoter Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108060009375 vtc4 Proteins 0.000 description 2
- 238000007805 zymography Methods 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- QXRNAOYBCYVZCD-BQBZGAKWSA-N (2S)-6-amino-2-[[(2S)-2-aminopropanoyl]amino]hexanoic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N 2-[[(2S)-2-[[(2S)-2-azaniumyl-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetate Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- 102100007877 APOE Human genes 0.000 description 1
- 101700025839 APOE Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- QADCERNTBWTXFV-JSGCOSHPSA-N Arg-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(O)=O)=CNC2=C1 QADCERNTBWTXFV-JSGCOSHPSA-N 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- IIFDPDVJAHQFSR-WHFBIAKZSA-N Asn-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O IIFDPDVJAHQFSR-WHFBIAKZSA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- SJUXYGVRSGTPMC-UHFFFAOYSA-N Asparaginyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CC(N)=O SJUXYGVRSGTPMC-UHFFFAOYSA-N 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- DYDKXJWQCIVTMR-UHFFFAOYSA-N Aspartyl-Methionine Chemical compound CSCCC(C(O)=O)NC(=O)C(N)CC(O)=O DYDKXJWQCIVTMR-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 102100014446 CYBB Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 208000002573 Connective Tissue Disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- AYKQJQVWUYEZNU-UHFFFAOYSA-N Cysteinyl-Asparagine Chemical compound SCC(N)C(=O)NC(C(O)=O)CC(N)=O AYKQJQVWUYEZNU-UHFFFAOYSA-N 0.000 description 1
- NXTYATMDWQYLGJ-UHFFFAOYSA-N Cysteinyl-Leucine Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CS NXTYATMDWQYLGJ-UHFFFAOYSA-N 0.000 description 1
- WXOFKRKAHJQKLT-UHFFFAOYSA-N Cysteinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CS WXOFKRKAHJQKLT-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N Cysteinyl-Phenylalanine Chemical compound SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 210000004395 Cytoplasmic Granules Anatomy 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 210000000285 Dendritic Cells, Follicular Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 108010013369 EC 3.4.21.9 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 206010063599 Exposure to chemical pollution Diseases 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 210000000497 Foam Cells Anatomy 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- 101710023881 HAPLN1 Proteins 0.000 description 1
- 102100005835 HAPLN1 Human genes 0.000 description 1
- 102100006110 HM13 Human genes 0.000 description 1
- HTOOKGDPMXSJSY-STQMWFEESA-N His-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 HTOOKGDPMXSJSY-STQMWFEESA-N 0.000 description 1
- WRPDZHJNLYNFFT-UHFFFAOYSA-N Histidinyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC1=CN=CN1 WRPDZHJNLYNFFT-UHFFFAOYSA-N 0.000 description 1
- 229940097277 Hygromycin B Drugs 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 210000004201 Immune Sera Anatomy 0.000 description 1
- 229940042743 Immune sera Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102100012486 JUN Human genes 0.000 description 1
- 108060001040 JUN Proteins 0.000 description 1
- 208000009883 Joint Disease Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 210000001865 Kupffer Cells Anatomy 0.000 description 1
- VYZAGTDAHUIRQA-WHFBIAKZSA-N L-alanyl-L-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-WHFBIAKZSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine zwitterion Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-N L-tyrosyl-L-arginine Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N L-tyrosyl-L-tyrosine Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 210000001821 Langerhans Cells Anatomy 0.000 description 1
- 229920000126 Latex Polymers 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 1
- OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- HGNRJCINZYHNOU-LURJTMIESA-N Lys-Gly Chemical compound NCCCC[C@H](N)C(=O)NCC(O)=O HGNRJCINZYHNOU-LURJTMIESA-N 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- MYTOTTSMVMWVJN-STQMWFEESA-N Lys-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MYTOTTSMVMWVJN-STQMWFEESA-N 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 101700019781 MMP1 Proteins 0.000 description 1
- 102100016820 MMP10 Human genes 0.000 description 1
- 101700040359 MMP3 Proteins 0.000 description 1
- 102100014892 MMP7 Human genes 0.000 description 1
- 101700057314 MMP7 Proteins 0.000 description 1
- 102100014897 MMP8 Human genes 0.000 description 1
- 101700067851 MMP9 Proteins 0.000 description 1
- 230000036882 MTD Effects 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 210000001132 Macrophages, Alveolar Anatomy 0.000 description 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
- 108010015302 Matrix Metalloproteinase 9 Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108009000330 Matrix Metalloproteinases Proteins 0.000 description 1
- IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 description 1
- KAKJTZWHIUWTTD-VQVTYTSYSA-N Met-Thr Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)O)C([O-])=O KAKJTZWHIUWTTD-VQVTYTSYSA-N 0.000 description 1
- PESQCPHRXOFIPX-RYUDHWBXSA-N Met-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-RYUDHWBXSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 206010048592 Musculoskeletal disease Diseases 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 210000004261 Periodontium Anatomy 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- KNPVDQMEHSCAGX-UHFFFAOYSA-N Phenylalanyl-Cysteine Chemical compound SCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 KNPVDQMEHSCAGX-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920000582 Polyisocyanurate Polymers 0.000 description 1
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 description 1
- BEPSGCXDIVACBU-UHFFFAOYSA-N Prolyl-Histidine Chemical compound C1CCNC1C(=O)NC(C(=O)O)CC1=CN=CN1 BEPSGCXDIVACBU-UHFFFAOYSA-N 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 229940024999 Proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- SBMNPABNWKXNBJ-UHFFFAOYSA-N Serinyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CO SBMNPABNWKXNBJ-UHFFFAOYSA-N 0.000 description 1
- LZLREEUGSYITMX-UHFFFAOYSA-N Serinyl-Tryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C(CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-UHFFFAOYSA-N 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000001768 Subcellular Fractions Anatomy 0.000 description 1
- 102100009508 TMPRSS15 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- IOWJRKAVLALBQB-IWGUZYHVSA-N Thr-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O IOWJRKAVLALBQB-IWGUZYHVSA-N 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- CUTPSEKWUPZFLV-UHFFFAOYSA-N Threoninyl-Cysteine Chemical compound CC(O)C(N)C(=O)NC(CS)C(O)=O CUTPSEKWUPZFLV-UHFFFAOYSA-N 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- UYKREHOKELZSPB-JTQLQIEISA-N Trp-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(O)=O)=CNC2=C1 UYKREHOKELZSPB-JTQLQIEISA-N 0.000 description 1
- TYYLDKGBCJGJGW-WMZOPIPTSA-N Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=C(O)C=C1 TYYLDKGBCJGJGW-WMZOPIPTSA-N 0.000 description 1
- YBRHKUNWEYBZGT-UHFFFAOYSA-N Tryptophyl-Threonine Chemical compound C1=CC=C2C(CC(N)C(=O)NC(C(O)C)C(O)=O)=CNC2=C1 YBRHKUNWEYBZGT-UHFFFAOYSA-N 0.000 description 1
- ZQOOYCZQENFIMC-STQMWFEESA-N Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=C(O)C=C1 ZQOOYCZQENFIMC-STQMWFEESA-N 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 210000003934 Vacuoles Anatomy 0.000 description 1
- WITCOKQIPFWQQD-FSPLSTOPSA-N Val-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O WITCOKQIPFWQQD-FSPLSTOPSA-N 0.000 description 1
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- VEYJKJORLPYVLO-RYUDHWBXSA-N Val-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VEYJKJORLPYVLO-RYUDHWBXSA-N 0.000 description 1
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 229920002847 antisense RNA Polymers 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 108010054191 butyrylesterase Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000035569 catabolism Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 201000009446 chronic granulomatous disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000000093 cytochemical Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002380 cytological Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910000078 germane Inorganic materials 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N gly pro Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 229940094991 herring sperm DNA Drugs 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002134 immunopathologic Effects 0.000 description 1
- 108060005990 imp1 Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl β-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003641 microbiacidal Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- XIVJNRXPRQKFRZ-UHFFFAOYSA-N naphthalen-1-yl butanoate Chemical compound C1=CC=C2C(OC(=O)CCC)=CC=CC2=C1 XIVJNRXPRQKFRZ-UHFFFAOYSA-N 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000003169 placental Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 210000004206 promonocyte Anatomy 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 108091006090 transcriptional activators Proteins 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Definitions
- the present invention is in the field of molecular biology; more particularly, the present invention describes a protein produced by human monocyte/macrophage cells and nucleic acid sequences encoding this protein. Specifically, the present invention describes a new metalloproteinase inhibitor, TIMP-3, which is produced by monocyte/macrophage cells and is useful for regulating tissue destruction by metalloproteinases .
- Monocytes/macrophages play a central role in host defense and the inflammatory process.
- Monocyte functions include phagocytosis and killing of pathogenic microorganisms, processing of antigens for "presentation" to T cells, antibody dependent and independent cytotoxicity, and secretion of numerous cytokines that play a key role in the interaction of monocyte/macrophages with a variety of lymphocytes and other cells to generate an inflammatory response. Therefore, characterizing the proteins produced by monocytes/macrophages, identifying the key proteins and developing immunoassays for the presence of monocytes in inflammation represents a significant advance in monocyte therapeutic and diagnostic approaches.
- Monocytes develop from monoblasts through promonocytes in the bone marrow and eventually join a pool of circulating mature monocytes which have a half-life in the blood stream of approximately three days. Roughly 75% of the circulating monocyte pool marginates along blood vessel walls. Monocytes randomly migrate to the tissues to become antigen presenting cells or phagocytic macrophages.
- the phagocytic macrophages include alveolar macrophages of the lung, bone marrow macrophages, and Kupffer cells of the liver.
- the antigen presenting or dendritic cells include the interdigitating reticular cells and follicular dendritic cells of the lymph nodes and the Langerhans cells of the skin.
- monocytes and macrophages play a key role in host defense both in the blood and in tissues. Characterizing a large number of the proteins synthesized by the monocyte/macrophage represents a major breakthrough in the study and development of therapeutic and diagnostic approaches to monocyte-mediated inflammatory events and provides a commercially useful library of monocyte/macrophage-derived polypeptides and cDNAs.
- Macrophages can be distinguished from monocytes by several different cellular characteristics. Precursor monocytes are rich in azurophilic peroxidase-containing cytoplasmic granules and contain large amounts of myeloperoxidase. Macrophages have more cell surface receptors by which they can "sense" their environment. These include receptors for: immunoglobulin and complement, growth factors, lipoproteins, peptides and polysaccharides. Binding of ligands to these receptors triggers macrophage proliferation, chemotaxis, secretion and phagocytosis--the process of moving materials into the cell. This type of activation enables these cells to intensify their killing of intracellular microorganisms.
- Macrophages In addition to the antimicrobial function of macrophages, these cells perform the functions of immunoregulation, inflammation, wound healing and the selective removal of tumor cells, senescent cells or those cells which are metabolically defective. Macrophages also have the capability to function as secretory and regulatory cells, producing many different substances involved in the inflammatory response. Macrophages play an important role in pathogenesis and disease states, and also in embryonic development and postnatal brain remodeling. Inherited diseases involving macrophages and monocytes include: 1) storage diseases manifesting a deficiency of degradative enzymes, 2) malignant osteoporosis, 3) chronic granulomatous disease, and 4) familial chronic mucocutaneous candidiasis. Some of these diseases may be able to be corrected.
- macrophage disorders can cause defective handling of bacteria upon infection, including improper bactericidal killing, bowel damage, arthritis, and toxic shock syndrome.
- Physical and chemical agents including trauma, smoking, UV irradiation, asbestos exposure and steroids can block proper functioning of macrophages and monocytes.
- Macrophages which accumulate cholesterol from blood lipoproteins become the foam cells of human atherosclerotic lesions.
- autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis cause abnormal function of monocytes.
- THP-1 CELLS THP-1 is a human leukemic cell line with distinct monocytic characteristics. This cell line was derived from the blood of a 1-year-old boy with acute monocytic leukemia (Tsuchiya et al . 1980 Int. J. Cancer 26.:171-176) .
- cytological and cytochemical criteria were used to determine the monocytic nature of the cell line: 1) the presence of ⁇ -naphthyl butyrate esterase activity which could be inhibited by NaF (sodium fluoride) , 2) the production of lysozyme, 3) the phagocytosis of latex particles and sensitized SRBC (sheep red blood cells) , and 4) the ability of mitomycin C-treated THP-1 cells to activate T-lymphocytes following ConA (concanavalin A) treatment.
- the cytoplasm contained small azurophilic granules, and the nucleus was indented and irregularly shaped with deep folds.
- the cell line had Fc and C3b receptors, probably functioning in phagocytosis.
- leukemia could be considered to represent an arrest in normal differentiation, and leukemic cell lines would reflect the "block" in differentiation intrinsic to the cells from which the line was derived.
- Many human myeloid and myelomonocytic cell lines retain some ability to differentiate into more mature phenotypes in response to various stimuli including growth factors, lymphokines, cytokines, vitamin D derivatives, and tumor promoters.
- THP-1 cells treated with the tumor promoter 12-0-tetradecanoyl-phorbol-13 acetate (TPA) will stop proliferating and differentiate into macrophage-like cells which mimic native monocyte-derived macrophages in several respects.
- THP-1 cells Morphologically, as the cells change shape the nucleus becomes more irregular and additional phagocytic vacuoles appear in the cytoplasm.
- the differentiated THP-1 cells also exhibit an increased adherence to tissue culture plastic.
- induced THP-1 cell lines also exhibit characteristic changes in gene expression.
- Proto-oncogenes are involved in the regulation of cellular proliferation and differentiation via various signal transduction pathways. They have been shown to undergo altered levels of expression following the differentiation of monocytes or myeloid cell lines into macrophages and can be used to monitor the maturation of myelomonocytic leukemia cells and the differentiation of THP-1 cells exposed to various inducing agents including TPA.
- LPL lipoprotein lipase
- apo E apolipoprotein E
- TPA lipopolysaccharide
- LPS lipopolysaccharide
- IL-1 antagonists secreted by PMA-differentiated THP-1 cells, have been shown to inhibit in vi tro activities of IL-1 and therefore could be useful in the development of anti-inflammatory molecules for chronic inflammatory disease (Bienkowski, M.J. et al . 1985 J. Biol . Chem. 265 :
- TRIP-3 The protein molecule of this invention (TIMP-3) is a novel member of a class of protease inhibitors known as tissue
- TIMPs inhibitors of metalloproteinases
- the key feature of these proteins lies in their ability to inhibit one or more of the metalloproteinases, a class of proteolytic enzymes that require a Zn ++ cation for activity.
- the inhibitor of this invention may
- the metalloproteinases are a multigene family which
- ECM extracellular matrix
- MMP-7 Uterine Metalloproteinase Fibronectin, Proteoglycan
- Metalloproteinases also proteolytically inactivate several members of a class of serine protease inhibitors (serpins) , which in turn function to regulate the activity of many potent serine proteases.
- serpins serine protease inhibitors
- the MMPs indirectly bring about the destruction of a variety of biologically important molecules by serine proteases.
- controlling the activity of the MMPs has indirect effects on activity of a range of other proteases.
- MMPs are capable of degrading many of the key structural component of tissues. This ability is utilized in normal processes where destruction of existing tissues is necessary, such as embryogenesis and tissue remodeling.
- Metalloproteinases have also been implicated in processes where their activity is more specifically directed, such as in the movement of cells through tissues.
- MMPs play an important role in a number of pathological processes.
- proteolysis of ECM components by MMPs is a major cause of synovial tissue destruction seen in these diseases (reviewed in Firestein, G.S. (1992) Curr. Opin. Rheumatol . ___, 348-54) .
- Metalloproteinases also participate in tumor metastasis. In order to reach secondary sites, primary tumor cells must first gain access to the circulation and later reenter the tissues. Both involve moving through tissues as well as the endothelial basement membrane. The degradative action of metalloproteases on these structures is critical for the migration of tumor cells (reviewed in Mignatti, P. and Rifkin, D.B. (1993) Physiol. Rev. 71:161-95) . MMPs have been implicated in periodontal disease.
- Tissue degradation is largely mediated by neutrophils attracted to the * inflammatory site, and secretion of neutrophil MMPs is believed to play a major role in tissue destruction (reviewed in Sodek, J. and Overall, CM. (1992) Matrix Suppl 1, 352-62) .
- Metalloproteinases participate in bone resorption process. Collagenase produced by osteoblast cells degrades collagen overlying the surface of the bone and affords osteoclasts access to underlying mineralized bone. The osteoclasts in turn utilize MMPs as well as other proteases in bone resorption. This bone catabolism affects the overall balance of deposition/resorption and resulting imbalance can lead to demineralization of the bone and osteoporosis (Everts, V. et al . (1992) J. Cell Physiol. 150:221-231: Vaes, G. et al . (1992) Matrix, Suppl . 1. 383-388) .
- MMP myeloma
- Inhibition of MMPs may have a therapeutic effect in prevention of corneal ulceration resulting from a broad variety of insults.
- TIMPs should be medically useful for treatment of pathological conditions involving MMPs including but not limited to those discussed above.
- TIMP-1 Docherty, A.J.P. et al . (1985) Nature 318:66-69
- the proteins are classified in the TIMP family based on their structural similarity to each other as well as their mutual ability to inhibit metalloproteinases. Although both human TIMPs inhibit a range of metalloproteinases, their specificities do differ.
- TIMP-2 is a more effective inhibitor of both 72kDa gelatinase (MMP-2) and 92kDa gelatinase (MMP-9)
- TIMP-1 * is the better inhibitor of MMP-1, interstitial collagenase (Howard, E.W. et al . (1991) J. Biol. Chem. 266:13070-75)
- IMPs inhibitors of metalloproteinases
- TIMP-1 and TIMP-2 are the only human TIMPs that have been fully characterized and cloned. It is impossible to know which of the activities described are due to novel members of the TIMP family or how many members of the TIMP family are encoded in the human genome.
- TIMPs have been cloned from other species including bovine TIMP-1 (Freudenstein et al . (1990) Biochem. Biophys. Res. Comm. 171:250-256) and TIMP-2 (Boone, T.C. et al . (1990) Proc. Natl. Acad. Sci. .87.:2800-2804) , urine TIMP-1 (Gewert, D.R. et al . (1987) EMBO J. 1:651-657) , rabbit TIMP-1 (Horowitz, S. et al. (1989) J. Biol. Chem. 264.7092-7095) and chicken TIMP-3 (Pavloff, N. et al .
- the subject invention provides a nucleotide sequence that uniquely identifies a novel human monocyte/macrophage derived protein. We designate this new gene "tissue inhibitor of metalloproteinases-3" or TIMP-3. Aspects of the subject invention include: purified TIMP-3; purified nucleotide sequences encoding all or a portion of said TIMP-3; recombinant- host cells or organisms for the production of TIMP-3; hybridization probes for detecting nucleotide sequences encoding TIMP-3; hybridization probes useful for regulating TIMP-3 gene transcription or translation; antibodies capable of specifically binding to TIMP-3; methods of detecting TIMP-3 with TIMP-3-specific antibodies, particularly in biological samples; methods of isolating recombinant or naturally-occurring TIMP-3 using TIMP-3- specific antibodies; methods of treating samples with TIMP-3 to inhibit proteolytic activity in the sample; pharmaceutical compositions comprising TIMP-3 in an acceptable excipient, and methods of treating diseases in which matrix metalloprotease
- Table 1 shows an amino acid homology analysis of chicken TIMP-3 and human TIMP-1, TIMP-2 and TIMP-3.
- the sequence of human TIMP-3 is also presented as SEQ ID NO: 2 of the Sequence Listing.
- Figure 1 shows an amino acid content graph of human TIMP - 1 .
- Figure 2 shows an amino acid content graph of human TIMP-2.
- Figure 3 shows an amino acid content graph of human TIMP-3.
- Figure 4 shows an isoelectric point curve of human TIMP-1.
- Figure 5 shows an isoelectric point curve of human TIMP-2.
- Figure 6 shows an isoelectric point curve of human TIMP-3.
- Figure 7 shows a hydrophobicity profile of human TIMP-1.
- Figure 8 shows a hydrophobicity profile of human TIMP-2.
- Figure 9 shows a hydrophobicity profile of human TIMP-3.
- Figures 10 A-C show RNA "Northern" blots of polyadenylated RNA isolated from various human tissues using a TIMP-3 probe.
- Figure 11 shows a Southern blot of human chromosomal DNA digested with various restriction enzymes, and hybridized with a TIMP-3 probe.
- Figures 12 A and B show a Southern blot of Eco RI- digested chromosomal DNA taken a variety of mammalian somatic cell hybrids that has been hybridized with a TIMP-3 probe.
- Figure 13 shows a "zoo" blot of Eco Rl-digested chromosomal DNA from a variety of mammalian sources that has been hybridized with a TIMP-3 probe.
- TIMP-3 refers to endogenously encoded, i.e., a naturally occurring, polypeptide expressed by human THP-1 cells activated with endotoxin having the amino acid sequence backbone described in SEQ ID NO: 2 in the Sequence Listing and to allelic variants, derivatives, fragments, or recombinant forms that retain the biological characteristics of the naturally occurring human TIMP-3, i.e., metalloproteinase inhibitory activity.
- naturally occurring TIMP-3 refers to TIMP-3 with a primary amino acid sequence that is the same as the primary amino acid sequence of a TIMP-3 produced by a non-genetically engineered human cell in vi tro or in vivo .
- TIMP-3 derivative is defined to include polypeptides possessing TIMP-3 biological activity and/or TIMP-3 immunological activity.
- biological activity or “biological characteristics” of a protein refers to the structural or biochemical function of * the protein in the normal biological processes of the organism in which the protein naturally occurs. Examples of biological characteristics of TIMP-3 include both its structure and/or conformation, which can be determined by specific antigenicity or immunogenicity, and the ability of the TIMP-3 to mediate inflammatory responses by the regulation of metalloproteinases in vivo .
- biological activity of TIMP-3 includes the range of biological characteristics associated with the native form of TIMP-3.
- TIMP-3 immunological activity it is intended that a polypeptide with TIMP-3 immunological activity can specifically bind with antibodies specific for TIMP-3, or can, upon injection into appropriate animals (with suitable adjuvants) , be used to induce an immune response specific for TIMP-3.
- TIMP-3 derivative means TIMP-3 derivatives with biological activity and TIMP-3 immunological activity (i.e. are immunologically cross-reactive with antibodies specific for TIMP-3) .
- TIMP-3 with TIMP-3 biological activity may have amino acid sequences that consist of the amino acid sequence of the naturally occurring TIMP-3 protein or the amino acid sequence of naturally occurring TIMP-3 protein with minor variations.
- TIMP-3 derivatives also include polypeptides with the amino acid sequence of TIMP-3 with one or more amino acid substitutions.
- these amino acid substitutions are the result of the substitution of one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine, i.e., conservative amino acid replacements.
- TIMP-3 derivatives may include polypeptides with the amino acid sequence of naturally occurring TIMP-3, but possessing various minor amino acid deletions and/or insertions, typically in the range of about 1 to 5 amino acids, as well as one or more amino acid substitutions.
- Guidance in determining which TIMP-3 amino acid residues may be replaced or deleted without abolishing TIMP-3 biological activities of interest may be found by searching computer libraries of protein amino acid sequences for proteins that are homologous to a given tissue inhibitor of metalloproteinases and minimizing the number of amino acid sequence changes in regions of homology between TIMP-3 and homologous proteins, such as TIMP-1 or TIMP-2, detected by a computer homology search.
- TIMP-3 amino acid residues that may be replaced or deleted without abolishing TIMP-3 biological activities of interest may be determined by systematically making insertions, deletions, or replacement of TIMP-3 amino acids (by recombinant DNA techniques) and assaying for the biological activities of interest.
- the TIMP-3 protein may or may not be post-translationally modified.
- a "Post-translational" modification includes processes such as proteolytic cleavage (including the action of signal peptidases) , glycosylation, lipidation, and the like. The nature of post-translational modification may vary in accordance with the type of cell in which TIMP-3 is produced.
- TIMP-3 is transcribed by endotoxin activated THP-1 cells
- the naturally occurring expression of TIMP-3 is not known to be limited to THP-1 cells or macrophages or monocytes.
- a “mutation” in a protein alters its primary structure (relative to the commonly occurring or specifically described protein) due to changes in the nucleotide sequence of the DNA which encodes the protein. These mutations include allelic variants. Mutational changes in the primary structure of a protein result from deletions, additions or substitutions.
- a “deletion” is defined as a change in a polypeptide sequence in which one or more internal amino acid residues are absent.
- An “addition” is defined as a change in a polypeptide sequence which has resulted in one or more additional internal amino acid residues as compared to the wild type.
- substitution results from the replacement of one or more amino acid residues by other residues .
- a protein "fragment” is a polypeptide consisting of a primary amino acid sequence which is identical to a portion of the primary sequence of the protein to which the polypeptide is related.
- a host cell “expresses” a gene or DNA when the gene or DNA is transcribed and the protein encoded by the transcribed RNA is produced by translation.
- the present invention provides for nucleotide sequences uniquely identifying TIMP-3, nucleotide sequences encoding TIMP-3, and purified TIMP-3.
- Nucleotide sequences encoding TIMP-3 have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization or PCR probes, use for chromosome and gene mapping, use in the recombinant production of TIMP-3, generation of anti-sense RNA, DNA or nucleotide analogues, and the like.
- the uses of oligonucleotides encoding TIMP-3 provided for in this application are exemplary of known techniques and are not intended to reflect any limitation on their use in any technique that would be known to the person of average skill in the art.
- nucleotide sequences provided for in this application may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of polynucleotide sequences that are currently known to the person of average skill in the art, e.g., the triplet genetic code, specific base pair interactions, etc. ' • It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of TIMP-3-encoding nucleotide sequences, some bearing minimal nucleotide sequence homology to the nucleotide sequence of the naturally occurring TIMP-3 gene, may be produced.
- nucleotide sequences of interest encoding TIMP-3 and TIMP-3 derivatives are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring TIMP-3 gene under stringent conditions, it may be advantageous to produce nucleotide sequences encoding TIMP-3 or TIMP-3 derivatives possessing a substantially different codon usage.
- Codons may be altered by chemical synthesis of the entire gene or relevant portions thereof, or by recombinant DNA methods including but not limited to site- directed mutagenesis (see generally, Ausubel, F.M. et al. (1989) in Current Protocols in Molecular Biology, John Wiley & Sons, and periodic updates thereof) . Codons can be selected to increase the rate at which expression of the protein or peptide occurs in a particular expression host organism in accordance with the frequency with which a particular codon is utilized by the host.
- RNA transcripts having more desirable properties e.g., a greater half-life, than transcripts produced from the naturally occurring TIMP-3 encoding nucleotide sequence and the like.
- Nucleotide sequences encoding TIMP-3 may be joined to a variety of other nucleotide sequences of interest by means of well established recombinant DNA techniques (see, for example, Sambrook et al . (1989) , Molecular Cloning: A Laboratory Manual, 2nd Ed.. Cold Spring Harbor) .
- Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, and the like.
- vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease digestion sites, and selectable markers for the host cell.
- Another aspect of the subject invention is to provide for TIMP-3-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding TIMP-3.
- Nucleic acid hybridization probes for the detection of TIMP-3 encoding nucleotide sequences should preferably contain at least 50% of the nucleotides from the sequence of a given TIMP-3 encoding nucleotide sequence.
- the hybridization probes of the subject invention may be derived from the nucleotide sequences of the Sequence Listing and the genomic sequences encoding TIMP-3 uniquely identified by the nucleotide sequences of the Sequence Listing.
- Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as 32 P or 35 S, or enzymatic labels such as alkaline phosphatase, coupled to the probe via avidin/biotin coupling systems, and the like.
- reporter groups including radionuclides such as 32 P or 35 S, or enzymatic labels such as alkaline phosphatase, coupled to the probe via avidin/biotin coupling systems, and the like.
- nucleic acid hybridization probes An additional use for nucleic acid hybridization probes involves their use as primers for PCR, the polymerase chain reaction.
- the polymerase chain reaction is described in detail in U.S. Patents 4,965,188 and 4,683,195 and 4,800,195.
- Probes for hybridization may be synthesized by both enzymatic and in vi tro techniques.
- Short hybridization probes are preferably synthesized by in vi tro methodology such as the use of commercially available DNA synthesizers like machines sold by Applied Biosystems.
- nucleotide sequences of lengths greater than 10 base pairs may be produced by commercially available machines.
- Oligonucleotides produced by in vitro synthesis may be readily spliced together using generally known recombinant DNA techniques to produce a longer sequence of interest .
- Other means of producing TIMP-3-specific hybridization probes include the cloning of nucleic acid sequences encoding TIMP-3 and TIMP-3 derivatives into vectors for the production of RNA probes .
- RNA polymerase as T7 or SP6 RNA polymerase, or the like, and the appropriate radioactively labeled nucleotides.
- Synthetic chemistry may be used to reproduce the entire sequence of a TIMP-3 encoding gene, any portion thereof, or to introduce in mutations into the sequence.
- the nucleotide sequence for TIMP-3 can be used to construct hybridization probes for mapping the TIMP-3 gene and for the genetic analysis of individuals with TIMP-3 genetic disorders, allelic variants or other genetic traits of interest.
- the nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosomes using well known genetic and/or chromosomal mapping techniques. These techniques include in si tu hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like.
- the technique of fluorescent in si tu hybridization of chromosome spreads has been described, among other places, in Verma et al .
- SUBSTITUTESHEET(RULE26. physical chromosomal map may be of particular interest in detecting genetic diseases in affected individuals and potential carriers of genetic diseases.
- the nucleotide sequence of the subject invention may be used to detect differences in the sequence of genes that vary between normal individuals and affected individuals.
- TIMP-3 may be used to produce purified TIMP-3 using well known methods of * recombinant DNA technology.
- TIMP-3 may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from species either the same or different than the species from which the TIMP-3 encoding nucleotide sequences are naturally present, i.e., endogenous.
- Advantages of producing the TIMP-3 by recombinant DNA technology include obtaining highly enriched sources of the proteins for purification and the availability of simplified purification procedures.
- TIMP-3 may be cultured under conditions favoring expression of the TIMP-3 sequence and the recovery of the recombinantly produced protein from the cell culture.
- TIMP-3 produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps will depend on the nature of the production and the particular TIMP-3 produced.
- TIMP-3 fragments may be produced by direct peptide synthesis using solid-phase techniques. See Stewart et al . , Solid-Phase Peptide Synthesis (1969) , W. H. Freeman Co., San Francisco, and Merrifield, J. Am. Chem. Soc. 8 ⁇ :2149-2154 (1963) .
- TIMP-3 TIMP-3-specific antibodies.
- induction of antibodies it is intended not only the stimulation of an immune response by injection into animals, but analogous steps in the production of synthetic antibodies or other specific-binding molecules such as the screening of recombinant immunoglobulin libraries, Orlandi, R. et al . , (1989) PNAS USA 8 . 6:3833-3837 or Huse, W.D.
- TIMP-3 for use in the induction of antibodies of interest does not need to have biological activity; however, TIMP-3 for use in the induction of antibodies will necessarily have immunological activity.
- Polypeptides for use in the induction of TIMP-3-specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, mimicking a portion of the amino acid sequence of TIMP-3, and may contain the entire amino acid sequence of naturally occurring TIMP-3 or a TIMP-3 derivative.
- An additional embodiment of the subject invention is the use of a composition comprising human TIMP-3, or derivatives thereof, as bioactive agents for the treatment of diseases including but not limited to: inflammation, arthritis, connective tissue disorders, periodontal disease, dermatological disorders, infection, ophthalmic disorders, corneal ulceration, orthopedic disorders, osteoporosis, autoimmune disease, and cancer.
- Compositions comprising TIMP- 3 or derivatives thereof may also find application as ingredients or medicinal components of cosmetic or topical compositions.
- an appropriate dosage of TIMP-3 or a TIMP-3 derivative may be determined by any of several well established methodologies. For instance, animal studies are commonly used to determine the maximal tolerable dose, or MTD, of bioactive agent per kilogram weight of the test subject. In general, at least one animal species tested is mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Before human studies of efficacy are undertaken, Phase I clinical studies in normal subjects help establish safe doses.
- bioactive agent may be complexed with a variety of well established compounds or structures that, for instance, enhance the stability of the bioactive agent, or otherwise enhance its pharmacological properties (e.g., increase in vivo half-life, reduce toxicity, etc.) .
- the bioactive agent may be introduced in vivo by any of a number of established methods.
- the agent may be administered by inhalation; by subcutaneous (sub-q) ; intravenous (I.V.) , intraperitoneal (I.P.) , intramuscular (I.M.) injection; or as a topically applied agent (transdermal patch, ointments, creams, salves, eye drops, and the like) .
- the human monocyte THP-1 cDNA library was custom constructed by Stratagene (Stratagene, 11099 M. Torrey Pines Rd., La Jolla, CA 92037) .
- Poly(A+)RNA (mRNA) was purified from THP-1 cells (cultured 48 hr with lOOnm TPA and 4 hr with l ⁇ g/ml LPS) .
- cDNA synthesis was primed separately " with both oligo dT and random hexamers and the two cDNA libraries were treated separately.
- Synthetic adaptor oligonucleotides were ligated onto cDNA ends enabling its insertion into Uni-ZAPTM vector system (Stratagene) , allowing high efficiency unidirectional (sense orientation) lambda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions. Finally, the two libraries were combined into a single library by mixing equal numbers of bacteriophage.
- the THP-1 cDNA library can be screened with either DNA probes or antibody probes and the pBluescript ® phagemid (Stratagene) can be rapidly excised in vivo .
- the phagemid allows the use of a plasmid system for: easy insert characterization, sequencing, site-directed mutagenesis, the creation of unidirectional deletions and expression of fusion proteins.
- the custom-constructed library phage particles were infected into E. coli host strain XLl-Blue ® (Stratagene) , which has a high transformation efficiency, increasing the probability of obtaining rare, under-represented clones in the cDNA library.
- the phagemid forms of individual cDNA clones were obtained by the in vivo excision process in which the host bacterial strain was coinfected with both the lambda library phage and an fl helper phage. Proteins derived from both the library-containing phage and the helper phage nicked the lambda DNA, initiated new DNA synthesis from defined sequences on the lambda target DNA and created a smaller, single stranded circular phagemid DNA molecule that included all DNA sequences of the pBluescript ® plasmid and the cDNA insert .
- the resulting phage containing the phagemid DNA were secreted from the cells, purified, and then used to re-infect fresh host cells, where the double stranded phagemid DNA was produced. Because the phagemid carries the gene for
- the newly-transformed bacteria are selected on medium containing ampicillin.
- Phagemid DNA was purified using the Magic MiniprepsTM DNA Purification System (Promega catalogue #A7100. Promega Corp., 2800 Woods Hollow Rd. , Madison, WI 53711) . This small-scale process provides a simple and reliable method for lysing the bacterial cells and rapidly isolating purified phagemid DNA using a proprietary DNA-binding resin. The DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.
- Phagemid DNA was also purified using the QIAwell-8 Plasmid Purification System from QIAGEN ® DNA Purification System (QIAGEN Inc., 9259 Eton Ave. , Chatsworth, CA 91311) .
- This product line provides a convenient, rapid and reliable high-throughput method for lysing the bacterial cells and isolating highly purified phagemid DNA using QIAGEN anion-exchange resin particles with EMPORETM membrane technology from 3M in a multiwell format.
- the DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.
- the cDNA inserts from random isolates of the THP-1 library were sequenced in part.
- Methods for DNA sequencing are well known in the art.
- Conventional enzymatic methods employ DNA polymerase Klenow fragment, SequenaseTM or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest.
- Methods have been developed for the use of both single- and double-stranded templates.
- the chain termination reaction products are usually electrophoresed on urea-polyacrylamide gels and are detected either by autoradiography (for radionuclide-labelled precursors) or by fluorescence (for fluorescent-labelled precursors) .
- Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that can be determined per day (such as the Applied Biosystems 373 DNA sequencer and Catalyst 800) .
- databases containing previously identified sequences are searched for areas of homology (similarity) .
- Such databases include Genbank and EMBL. Two homology search algorithms were used.
- the first algorithm was originally developed by D.J.
- the homologous regions are searched in a two step manner.
- the highest homologous regions are determined by calculating a matching score using a homology score table.
- the parameter 'Ktup' is used in this step to establish the minimum window size to be shifted for comparing two sequences. Ktup also sets the number of bases that must match to extract the highest homologous region among the sequences.
- no insertions or deletions are applied and the homology is displayed as an initial (INIT) value.
- the homologous regions are aligned to obtain the highest matching score by inserting a gap in order to add a probable deleted portion.
- the matching score obtained in the first step is recalculated using the homology score Table and the insertion score Table to an optimized (OPT) value in the final output.
- DNA homologies between two sequences can be examined graphically using the Harr method of constructing dot matrix homology plots (Needleman, S.B. and Wunsch, CO., (1970) J. Mol . Biol. .48.:443) . This method produces a two-dimensional plot which can be useful in determining regions of homology versus regions of repetition.
- the second algorithm was developed by Applied Biosystems Inc. and has been incorporated into the Inherit 670 Sequence Analysis System.
- Pattern Specification Language developed by TRW Inc.
- TRW Inc. is used to determine regions of homology.
- window size There are three parameters that determine how the sequence comparisons are run: window size, window offset, and error tolerance.
- the DNA database is searched for sequences containing regions of homology and the appropriate sequences are scored with an initial value. Subsequently, these homologous regions are examined using dot matrix homology plots to determine regions of homology versus regions of repetition. Smith-Waterman alignments were used to display the results of the homology search.
- sequences from the cDNA clones were classified as to whether they are exact matches (regions of exact homology) , homologous human matches (regions of high similarity, but not exact matches) , homologous non-human matches (regions of high similarity present in species other than human) , or nonmatches (no significant regions of homology to previously identified nucleotide sequences) .
- Searches of the deduced proteins and peptides are done in a manner analogous to that done with the cDNA sequences.
- the sequence of the protein is used as a query sequence and compared to the previously identified sequences contained in a database such as Swiss/Prot or the NBRF Protein database to find homologous proteins.
- proteins are initially scored for homology using a homology score Table (Orcutt, B.C. and Dayhoff, M.O. Scoring Matrices, PIR Report MAT - 0285 (February 1985)) resulting in an INIT score.
- the homologous regions are aligned to obtain the highest matching scores by inserting a gap which adds a probable deleted portion.
- the matching score is recalculated using the homology score Table and the insertion score Table resulting in an optimized (OPT) score.
- OPT optimized
- Peptide and protein sequence homologies can also be ascertained using the Inherit 670 Sequence Analysis System in an analogous way to that used in DNA sequence homologies .
- Pattern Specification Language and parameter windows are used to search protein databases for sequences containing regions of homology which are scored with an initial value. Subsequent examination with a dot-matrix homology plot determines regions of homology versus regions of repetition.
- Incyte template #12006 was found to be homologous to members of the TIMP family, a family of homologous proteins which are known to be inhibitors of the matrix metalloproteinases.
- the best match was found to be with GENBANK entry CHKHIMP3A, the entry for a chicken TIMP.
- Template #12006 was also found to be homologous to several other members of the TIMP family from a variety of species. The Document Hit scores for all homologies detected were low, identifying template #12006 as a homolog for the database entries rather than an exact match.
- the homology between human TIMP-3 and human TIMP-1 and TIMP-2 as well as chicken TIMP-3 is shown in Table 1.
- the predicted isoelectric points for human TIMPs 1-3 were measured and these data are presented in Figures 4-6.
- the human TIMPs comprise the following number of charged amino acids, N- and C-termini, and isoelectric points: 5 Isoelectric Point [pi] 8.00 6.45 9.04
- a new gene whose function it may be desirable to inhibit or turn-off may be manipulated.
- a new gene whose function is related to a human disorder can be treated therapeutically by administration (either orally or intravenously) of antisense DNA, RNA or nucleotide derivatives which hybridize to DNA to shut off transcription of the offending or diseased gene.
- antisense DNA, RNA or nucleotide derivatives which hybridize to DNA to shut off transcription of the offending or diseased gene.
- Such technology is now well known in the art, and can be designed at various locations within the coded gene sequence.
- such inhibition can be achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing.
- modifications of gene expression can be obtained by designing antisense probes to extragenic regions such as promoter regions, enhancer regions, or even to other genes which control or inhibit the synthesis of the gene of interest .
- the library cloning vector used for the generation of the THP-1 library includes provisions for direct expression of the included sequence in E. coli: upstream of the cloning site lies a promoter for /S-galactosidase, followed by the amino-terminal Met and subsequent 7 residues of / S-galactosidase. Immediately following this is an engineered bacteriophage promoter (useful for artificial priming and transcription) , and other included unique restriction sites, up to and including the Eco RI cloning site and subsequent cDNA insert .
- the proper reading frame can be obtained by deletion or insertion of the appropriate bases by well known methods including in vi tro mutagenesis, nuclease digestion, or oligonucleotide linker inclusion, and used subsequently for bacterial expression studies as described.
- Oligonucleotide amplimers containing cloning sites as well as a segment of DNA sufficient to hybridize to stretches at both ends of the target cDNA (25 bases) can be synthesized chemically by standard methods . These primers can then used to amplify the desired gene segments by Polymerase Chain Reaction (PCR) . The resulting new gene segments can be digested with the corresponding restriction enzyme under standard conditions and isolated by gel electrophoresis.
- PCR Polymerase Chain Reaction
- similar gene segments can be produced by digestion of the cDNA itself with appropriate restriction enzymes and filling in missing gene segments with chemically synthesized oligonucleotides.
- These segments of coding sequence can be ligated together and cloned into appropriate expression vectors which would allow recombinant production of the encoded sequence.
- Suitable expression systems for such chimeric molecules include but are not limited to mammalian cells such as CHO cells, fungi, such as yeast, insect cells and viruses, such as Baculovirus, and bacteria such as E. coli .
- a useful expression vector may include a selectable phenotypic marker, e.g., an antibiotic resistance gene, such as ⁇ -lactamase, that would allow selection of recombinant clones; a second selectable marker to allow selection on the host cells containing the expression vector, such as neomycin phosphotransferase; replication origin to allow propagation in bacteria; a high level promoter driving a gene inserted into an insertion site, such as retroviral long terminal repeat (LTR) promoter/enhancers, the MMTV, SV40, or metallothionine promoter for CHO cells, the trp, lac, tac or T7 promoter for bacterial hosts, or the alpha factor or PGH promoters in yeast; transcription enhancers for the mammalian hosts, such as the RSV enhancer; and a polyadenylation site, AATAAA, if one does not exist within the cDNA sequence.
- a selectable phenotypic marker e.g.
- TIMP-3 may be expressed recombinantly in such a way as to facilitate purification of the TIMP-3 protein.
- Such an approach involves expression of the TIMP-3 as a chineric protein with one or more additional polypeptide modules; these modules provide for a general method for purification of the chimeric proteins.
- the term "module" refers to a domain of a protein not naturally present on naturally occurring TIMP-3.
- Such purification facilitating modules include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification utilizing immobilized metals, protein A extensions that allow purification on immobilized immunoglobulin, and the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA) .
- the inclusion of a linker sequence such as Factor XA or enterokinase may be useful to facilitate subsequent cleavage of the intact TIMP-3 protein.
- ANTI-TIMP-3 ANTIBODIES Two approaches are utilized to raise antibodies to TIMP-3 and both approaches can be used to generate either polyclonal or monoclonal antibodies.
- a denatured protein from the reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein can be used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize rabbit.
- the denatured protein can be radioiodinated and used to screen murine B-cell hybridomas for those which produce antibody.
- TIMP-3 amino acid sequence of TIMP-3, as deduced from the TIMP-3-cDNA, is analyzed to determine regions of high immunogenicity.
- the corresponding polypeptides are synthesized and are used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by, for example, Ausubel, F.M. et al., in Current Protocols in Molecular Biology, John Wiley __ Sons, Vol. 2, Sec. IV, pp 11.14.1, 1989.
- the optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and intervening regions of the polypeptide, which are likely to be exposed to the external environment when the protein is in its natural conformation (usually the most hydrophilic regions of the molecule) .
- selected peptides about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (See Ausubel et al . , supra at pp 11.15.1) .
- a cysteine may be introduced at the N-terminus of the peptide to permit coupling to KLH.
- Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant.
- the resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with antisera, washing and reacting with radioiodinated affinity purified specific goat anti-rabbit IgG.
- Hybridomas may be also be prepared and screened using standard techniques. Hybridomas of interest are detected by screening with radioiodinated TIMP-3 to identify those fusions producing the monoclonal antibody with the desired specificity.
- wells of plates FAST, Becton-Dickinson, Palo Alto, CA
- affinity purified specific rabbit-anti-mouse (or suitable' anti-species Ig) antibodies at 10 mg/ml.
- the coated wells are blocked with 1% BSA, washed and exposed to supernatants from hybridomas. After incubation the wells are exposed to radiolabeled TIMP-3, 1 mg/ml.
- Clones producing antibodies will bind a quantity of radioactivity which is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning at 0.3 cells/well. Cloned hybridomas are injected into pristine treated mice to produce ascites, and monoclonal antibody is 5 purified from the ascitic fluid by affinity chromatography on Protein A.
- TIMP-3 specific antibodies may be useful for the following reasons.
- TIMP-3 15 or monoclonal antibodies specific for TIMP-3, are known in the art, e.g., competitive binding assays and immunoradiometric assays .
- Immunoassays typically involve the formation of complexes between TIMP-3 and a TIMP-3-specific antibody (or similar TIMP-3-specific molecule) and the measurement of
- a two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on TIMP-3 is preferred, but a competitive binding assay may also be employed. These assays are described, among other places, in Maddox, D.E. et al., J. Exp. Med. (1983)
- Immunoassay procedures are utilized to measure several major parameters in immunopathologic and prepathologic conditions which are characterized by TIMP-3 abnormalities, e.g., the increased or decreased production of TIMP-3 by
- TIMP-3 in monocyte/macrophages 35 mononuclear cells from normal individuals are prepared using Ficoll-Paque (Pharmacia) and analyzed as described by Marra et al . (1991) J. Immun. 148:532-537.
- the quantity of TIMP-3 in monocyte/macrophages may be determined by performing immunoassays on freeze-thawed detergent extracts of cell suspensions enriched for monocyte/macrophages and comparing the slope of the binding curves to comparable binding curves generated by the purified protein.
- Native or recombinant TIMP-3 may be purified by immunoaffinity chromatography using TIMP-3-specific antibodies.
- an immunoaffinity column is constructed by covalently coupling the anti-TIMP-3 antibody to an activated chromatographic resin.
- Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, NJ) .
- monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A.
- Partially purified Ig is covalently attached to a chromatographic resin, for example CnBr activated Sepharose (Pharmacia LKB Biotechnology, Piscataway, NJ) . The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturers instructions .
- Such an immunoaffinity column is utilized in the purification of TIMP-3 by preparing a fraction from cells containing TIMP-3 in a soluble form.
- This preparation may be derived by solubilization of the whole cell, e.g., by the addition of detergent, or by the similar solubilization of a subcellular fraction by well known methods, e.g., differential centrifugation.
- the soluble TIMP-3 may be secreted into the medium conditioned by growth of cells that express TIMP-3 in useful quantity.
- a soluble TIMP-3 containing preparation is passed over the immunoaffinity column and the column is washed under conditions that allow the preferential absorbance of TIMP-3, for example, in high ionic strength buffers in the presence of detergent.
- the column is then eluted under conditions that disrupt antibody/TIMP-3 binding, e.g., a buffer of pH 2-3 or the presence of high concentration of a chaotrope, e.g. urea or the thiocyanate ion.
- clones 12006, 12417, and 12777 were discovered to contain TIMP-3 encoding sequence, and overlapped each other, implying discrete reverse transcriptase termination * sites.
- the cDNA insert from clone 12006 was excised from the clone DNA via restriction enzyme digestion, and was used as a hybridization probe against the THP-1 library. Hybridized under normal stringency conditions, 19 clones were detected by autoradiography.
- the other was complementary to bases 12 through 38 of the clone 12006 sequence (5'-TAC ATC CAT ACG GAA GTT TCC GAG AGT-3'; SEQ ID NO: 4) .
- the clone (IMP1) showing the longest PCR product (about 600 nucleotides) was purified to homogeneity, excised, amplified, extracted and sequenced by standard methods. The sequence included all of the putative amino acid coding regions for TIMP-3, and is shown as SEQ ID NO: 1 in the Sequence Listing. XIII. NORTHERN AND SOUTHERN BLOTS
- a probe was prepared by labeling insert from clone 12006 to a specific activity of approximately 1 x 10 9 cpm/ ⁇ g, using ⁇ _ 32 p 3CTP (3000Ci/mmol, Amersham, Arlington Heights, IL) with a commercially available random primer labeling kit (Promega Corp., 2800 Woods Hollow Rd. , Madison, WI 53711) .
- Multi- Tissue Northern (MTN) blots and the genomic Southern blot (GENO-BLOTTM) were obtained from Clontech, Inc., Palt. Alto, CA.
- chromosomal localization blot (BIOSMAPTM; BIOS Inc., New Haven, CT) were probed under standard high stringency conditions (hybridization: 5xSSPE, lOx Denhardt's, 0.1 mg/ml herring sperm DNA, 50% formamide, 2% SDS, 42°C; wash: 60°C, 0.2xSSC, 0.1% SDS) . All northern and Southern ' exposures used Kodak XAR-2 film with 2 L-PLUS intensifying screens (Fisher Biotech Inc., Pittsburgh, PA) at -70°C.
- Tissue-specific transcription of TIMP-3 was examined by RNA blot analysis using 3 ug poly A+ RNA per lane.
- a PCR- generated TIMP-3 clone insert was used as the hybridization probe.
- Figures 10 A and 10 B contain normal adult tissues;
- Fig. 10 C contains human fetal tissues.
- the lanes correspond to spleen (1) , thymus (2) , prostate (3) , testis (4) , ovary (5) , small intestine (6) , colon (7) , peripheral blood leukocyte (8) , heart (9) , brain (10) , placenta (11) , lung (12) , liver (13) , skeletal muscle (14) , kidney (15) , pancreas (16) , fetal heart (17) , fetal brain (18) , fetal lung (19) , fetal liver (20) , and fetal kidney (21) .
- Molecular weight standards are shown along the left side of the blot.
- Transcripts of 5.0, 2.6, and 2.4 kB were detected in all tissues examined and the 5.0 kB band represented at least 90% of the hybridization signal in most tissues. The ratio between the three bands seemed relatively invariant, except in the placental sample, where the relative levels of the 2.6 and 2.4 kB bands were much greater.
- the strongest hybridization signals were found in spleen, prostate, ovary, small intestine, heart, placenta, lung, and kidney. Significantly less TIMP-3 mRNA was detectable in colon, peripheral blood leukocytes, brain, liver, and pancreas although all three bands were clearly present.
- the profile was similar for fetal tissues; however, both fetal heart and liver contained increased levels of TIMP-3 mRNA relative to adult tissue.
- both fetal heart and liver contained increased levels of TIMP-3 mRNA relative to adult tissue.
- TIMP-3 cDNA was used as a hybridization probe against blots of human chromosomal DNA digested with Eco RI (lane 2) , Hind III (lane 3) , Bam HI (lane 4) , Ps"t I (lane 5) , and Bgl II (lane 6) .
- Eco RI Lane 2
- Hind III Lane 3
- Bam HI Lane 4
- Ps"t I Lane 5
- Bgl II Molecular weight standards are shown
- the TIMP-3 probe was hybridized to a blot of EcoRI-digested chromosomal DNA from 20 mouse/human and hamster/human somatic cell hybrids. Such blots are often useful for assigning genes to individual human chromosomes. Included are hamster DNA (lanes 1 and 15) , human DNA (lane 2 and 16) , mouse DNA (lane 1 and 15).
- Lane 8 represents chromosomes 1, 5, 12, 14,19, 21, and 22; lane 17, chromosomes 4, 5, 8, 22, X; lane 27, chromosomes 1, 5, 13, 19, 21, and 22.
- the 2.4 kB hybridization signals that correspond to the human gene were
- Lane 1 contained molecular weight standards. Signals of similar intensity and size were seen in lanes corresponding to human, monkey, dog, and cow. A distinct band of smaller size was visible in mouse DNA (lane 5) . No discrete bands could be discerned in the lanes corresponding to rat, rabbit, chicken or yeast DNA.
- the full length cDNA for TIMP-3 including the native leader sequence was cloned into pCEP-4 (Invitrogen, San Diego, CA) using standard PCR techniques.
- pCEP-4 was introduced into competent E. coli strain DH5-c_ using standard heat-shock procedures.
- Amplified plasmid DNA was isolated, purified using the Qiagen ® DNA Purification System (Qiagen, Chatsworth, CA 91311) , and used to transfect appropriate host cells such as Chinese Hamster ovary (CHO) , human 293 cells, Sf9 insect cells, or yeast, _____ cerevisiae, cells.
- Host cells 293-EBNA (Invitrogen, San Diego, CA) were transformed with the expression plasmid containing the TIMP-3 gene by lipofection (Gibco BRL, Grand Island, NY) according to standard protocol .
- Cells harboring plasmids were selected in REM (JRH Biosciences, Woodland, CA) or other similar basal medium such as DMEM/F12 (Gibco BRL) , 10% calf serum, and 2 mM L-glutamine supplemented with 250 ⁇ g/ml geneticin (Gibco BRL) and 400 ⁇ g/ml hygromycin B (Calbiochem, La Jolla, CA) .
- T-flasks Costar, Cambridge, MA
- 500 ml spinner flasks Corning, Corning, NY
- the protein, TIMP-3 was secreted from cells grown in modified 3L Bellco spinner flasks (Bellco, Vineland, NJ) . Cells were harvested from the conditioned medium by centrifugation.
- TIMP-3 ZYMOGRAPHY Because chicken TIMP-3 is known to bind to extracellular matrix (ECM) , human TIMP-3 was tested for its ability to do the same. ECM was extracted from the surface of culture vessels upon which THP-1 cells had grown and also from the outer membrane of THP-1 suspension culture cells. Aliquots of conditioned media, previously discussed above, and ECM from both vessels and suspension culture cells were electrophoresed to separate their various proteins. The resulting gel was soaked in collagen and subsequently digested with collagenase. The bands which were evident on the resulting zymogram are those of peptides that inhibit collagenase. TIMP-3 presence, size, and activity were verified using this reverse zymography process (Tyagi, S.C. et al . (1993) Mol . Cell. Biol. !26_:49-59) .
- Antibodies were produced against peptides from two different hydrophilic regions of TIMP-3. These peptides were synthesized on an Applied Biosystems Peptide Synthesizer model 431A using Fmoc chemistry as specified by the manufacturer. The first synthetic peptide covered TIMP-3 amino acids 20 to 33, or RAKWGKKLVKEG (SEQ ID NO:5) . The second synthetic peptide covered TIMP-3 amino acids 172-187, or YRGWAPPDKSIINATD (SEQ ID NO:6) .
- TIMP- 3/20-33 and TIMP-3/172-187 were conjugated to the carrier protein, keyhole limpet hemocyanin (KLH) using the Pierce Imject ® Activated Immunogen Conjugation Kit.
- KLH- conjugates were injected into female New Zealand white rabbits. Two booster inoculations were given at two and four weeks after the primary injection.
- Antisera were collected and titered against BSA-TIMP-3 conjugates using standard ELISA protocol. Both TIMP-3 antisera preparations had titers of 1:8000.
- MOLECULE TYPE Chemically Synthesized Oligonucleotide
- xi SEQUENCE DESCRIPTION: SEQ ID NO: 2: AGCTCGAAAT TAACCCTCAC TAAAG 25
- MOLECULE TYPE Chemically Synthesized Oligonucleotide
- xi SEQUENCE DESCRIPTION: SEQ ID NO: 3: TACATCCATA CGGAAGTTTC CGAGAGT 27
Abstract
The present invention provides nucleotide sequences that identify TIMP-3 produced by human macrophages and/or monocytes. The present invention also provides for nucleotide sequences encoding TIMP-3, expression vectors for the production of purified TIMP-3, antibodies capable of specifically binding to TIMP-3, hybridization probes for the detection of TIMP-3 encoding nucleotide sequences, and genetically engineered host cells for the expression of TIMP-3.
Description
NOVEL HUMAN MONOCYTE/MACROPHAGE-DERIVED METALLOPROTEINASE INHIBITOR
FIELD OF THE INVENTION
The present invention is in the field of molecular biology; more particularly, the present invention describes a protein produced by human monocyte/macrophage cells and nucleic acid sequences encoding this protein. Specifically, the present invention describes a new metalloproteinase inhibitor, TIMP-3, which is produced by monocyte/macrophage cells and is useful for regulating tissue destruction by metalloproteinases .
BACKGROUND OF THE INVENTION
Monocytes/macrophages play a central role in host defense and the inflammatory process. Monocyte functions include phagocytosis and killing of pathogenic microorganisms, processing of antigens for "presentation" to T cells, antibody dependent and independent cytotoxicity, and secretion of numerous cytokines that play a key role in the interaction of monocyte/macrophages with a variety of lymphocytes and other cells to generate an inflammatory response. Therefore, characterizing the proteins produced by monocytes/macrophages, identifying the key proteins and developing immunoassays for the presence of monocytes in inflammation represents a significant advance in monocyte therapeutic and diagnostic approaches.
Monocytes develop from monoblasts through promonocytes in the bone marrow and eventually join a pool of circulating mature monocytes which have a half-life in the blood stream of approximately three days. Roughly 75% of the circulating monocyte pool marginates along blood vessel walls. Monocytes randomly migrate to the tissues to become antigen presenting cells or phagocytic macrophages. The phagocytic macrophages include alveolar macrophages of the lung, bone marrow macrophages, and Kupffer cells of the liver. The antigen presenting or dendritic cells include the interdigitating reticular cells and follicular dendritic cells of the lymph nodes and the Langerhans cells of the skin. Thus monocytes
and macrophages play a key role in host defense both in the blood and in tissues. Characterizing a large number of the proteins synthesized by the monocyte/macrophage represents a major breakthrough in the study and development of therapeutic and diagnostic approaches to monocyte-mediated inflammatory events and provides a commercially useful library of monocyte/macrophage-derived polypeptides and cDNAs.
Macrophages can be distinguished from monocytes by several different cellular characteristics. Precursor monocytes are rich in azurophilic peroxidase-containing cytoplasmic granules and contain large amounts of myeloperoxidase. Macrophages have more cell surface receptors by which they can "sense" their environment. These include receptors for: immunoglobulin and complement, growth factors, lipoproteins, peptides and polysaccharides. Binding of ligands to these receptors triggers macrophage proliferation, chemotaxis, secretion and phagocytosis--the process of moving materials into the cell. This type of activation enables these cells to intensify their killing of intracellular microorganisms. In addition to the antimicrobial function of macrophages, these cells perform the functions of immunoregulation, inflammation, wound healing and the selective removal of tumor cells, senescent cells or those cells which are metabolically defective. Macrophages also have the capability to function as secretory and regulatory cells, producing many different substances involved in the inflammatory response. Macrophages play an important role in pathogenesis and disease states, and also in embryonic development and postnatal brain remodeling. Inherited diseases involving macrophages and monocytes include: 1) storage diseases manifesting a deficiency of degradative enzymes, 2) malignant osteoporosis, 3) chronic granulomatous disease, and 4) familial chronic mucocutaneous candidiasis. Some of these diseases may be able to be corrected. by bone marrow transplant or retroviral mediated gene transfer. In addition, macrophage disorders can cause defective handling of bacteria upon infection, including improper bactericidal killing, bowel damage, arthritis, and toxic shock syndrome.
Physical and chemical agents, including trauma, smoking, UV irradiation, asbestos exposure and steroids can block proper functioning of macrophages and monocytes. Macrophages which accumulate cholesterol from blood lipoproteins become the foam cells of human atherosclerotic lesions. Finally, autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis cause abnormal function of monocytes.
THP-1 CELLS THP-1 is a human leukemic cell line with distinct monocytic characteristics. This cell line was derived from the blood of a 1-year-old boy with acute monocytic leukemia (Tsuchiya et al . 1980 Int. J. Cancer 26.:171-176) . The following cytological and cytochemical criteria were used to determine the monocytic nature of the cell line: 1) the presence of α-naphthyl butyrate esterase activity which could be inhibited by NaF (sodium fluoride) , 2) the production of lysozyme, 3) the phagocytosis of latex particles and sensitized SRBC (sheep red blood cells) , and 4) the ability of mitomycin C-treated THP-1 cells to activate T-lymphocytes following ConA (concanavalin A) treatment. Morphologically, the cytoplasm contained small azurophilic granules, and the nucleus was indented and irregularly shaped with deep folds. The cell line had Fc and C3b receptors, probably functioning in phagocytosis.
If one looks at the continuum of normal hematopoietic differentiation, leukemia could be considered to represent an arrest in normal differentiation, and leukemic cell lines would reflect the "block" in differentiation intrinsic to the cells from which the line was derived. Many human myeloid and myelomonocytic cell lines retain some ability to differentiate into more mature phenotypes in response to various stimuli including growth factors, lymphokines, cytokines, vitamin D derivatives, and tumor promoters. THP-1 cells treated with the tumor promoter 12-0-tetradecanoyl-phorbol-13 acetate (TPA) will stop proliferating and differentiate into macrophage-like cells which mimic native monocyte-derived macrophages in several respects. Morphologically, as the cells change shape
the nucleus becomes more irregular and additional phagocytic vacuoles appear in the cytoplasm. The differentiated THP-1 cells also exhibit an increased adherence to tissue culture plastic. In addition to physical changes, induced THP-1 cell lines also exhibit characteristic changes in gene expression. Proto-oncogenes are involved in the regulation of cellular proliferation and differentiation via various signal transduction pathways. They have been shown to undergo altered levels of expression following the differentiation of monocytes or myeloid cell lines into macrophages and can be used to monitor the maturation of myelomonocytic leukemia cells and the differentiation of THP-1 cells exposed to various inducing agents including TPA. C-fos and c-jun, transcriptional activators, are coinduced upon differentiation, c-myc remains unchanged, and c-myb is down-regulated during the differentiation of these cells (Auwerz, J. 1991 Experientia 47.:22-30) .
As myeloid precursor cells differentiate into mature cells, an observed change in membrane molecules is associated with the acquisition of both phagocytic and microbicidal capabilities involved in the host defense response. Following TPA induction of THP-1 cells, an increase in density of the complement C3b receptor and decrease in both FcR and CD4 is observed, the later being an adhesion molecule. These changes are also associated with the maturation of peripheral blood monocytes into macrophages.
Another characteristic of macrophages is the ability to respond to physiological stimuli by the secretion of a wide range of physiologically active molecules, including peptide hormones, cytokines, enzymes, and reactive oxygen species. Two proteins involved in lipid metabolism and also associated with atherosclerotic lesions are lipoprotein lipase (LPL) and apolipoprotein E (apo E) both produced by THP-1 cells and macrophages. LPL is responsible for the hydrolysis of the core triglycerides in triglyceride-rich lipoproteins to glycerol and free fatty acids and is expressed in THP-1 cells following TPA-induced differentiation. Apo E, an important
component of several plasma lipoproteins, is associated with the redistribution of cholesterol between cells and tissues and also increases following differentiation.
Once monocytes have matured into macrophages, distinct 5 patterns of cytokine production are associated with the "activation" of these cells. Discrete stimuli cause these activated macrophages to secrete several proinflammatory cytokines, including IL-lβ and TNF, both of which elicit potent biological effects contributing to the inflammatory
10 joint disease and bone destruction that characterize rheumatoid arthritis. Both TPA and lipopolysaccharide (LPS or "endotoxin") induce expression of IL-l in THP-1 cells, with TPA "priming" the macrophages for enhanced secretion (Cochran, F.R. and Finch-Arietta, M.B. 1989 Agents and Actions 27 :
15 271-273) . IL-1 antagonists, secreted by PMA-differentiated THP-1 cells, have been shown to inhibit in vi tro activities of IL-1 and therefore could be useful in the development of anti-inflammatory molecules for chronic inflammatory disease (Bienkowski, M.J. et al . 1985 J. Biol . Chem. 265 :
20 14505-14511) .
MATRIX METALLOPROTEASES (MMPs) AND INHIBITORS
The protein molecule of this invention (TIMP-3) is a novel member of a class of protease inhibitors known as tissue
25 inhibitors of metalloproteinases (TIMPs) . As is implied by their name, the key feature of these proteins lies in their ability to inhibit one or more of the metalloproteinases, a class of proteolytic enzymes that require a Zn++ cation for activity. Insofar as the inhibitor of this invention may
30 inhibit any one or several of the metalloproteinases, a consideration of the function and importance of the metalloproteinases is germane to understanding the potential utility of the inhibitor.
The metalloproteinases are a multigene family which
35 participate in a variety of biologically important processes by virtue of their ability to degrade many components of extracellular matrix (ECM) . Below is a table of the reported
human metalloproteinases and a partial listing of known ECM substrates .
MMP-l Interstitial collagenase Collagens I, II, III, VII, X
MMP-8 Neutrophil collagenase Collagens I, II, III
MMP-2 72 kDa gelatinase Collagens IV, V, VII, X, Fibronectin, Elastin
MMP-9 92 kDa gelatinase Collagens III, IV, V, IX
MMP-3 Stromelysin Collagens I, II, III, Fibronectin, Laminin, Proteoglycan link protein
M P-10 Stromelysin-2 Fibronectin, Collagens III, IV, V
MMP-7 Uterine Metalloproteinase Fibronectin, Proteoglycan
Metalloproteinases also proteolytically inactivate several members of a class of serine protease inhibitors (serpins) , which in turn function to regulate the activity of many potent serine proteases. By destroying the serpins, the MMPs indirectly bring about the destruction of a variety of biologically important molecules by serine proteases. Thus, controlling the activity of the MMPs has indirect effects on activity of a range of other proteases.
As can be seen from the substrates listed in the table, MMPs are capable of degrading many of the key structural component of tissues. This ability is utilized in normal processes where destruction of existing tissues is necessary, such as embryogenesis and tissue remodeling.
Metalloproteinases have also been implicated in processes where their activity is more specifically directed, such as in the movement of cells through tissues.
In addition, the MMPs play an important role in a number of pathological processes. In rheumatoid and other forms of arthritis, proteolysis of ECM components by MMPs is a major cause of synovial tissue destruction seen in these diseases (reviewed in Firestein, G.S. (1992) Curr. Opin. Rheumatol . ___, 348-54) . Metalloproteinases also participate in tumor metastasis. In order to reach secondary sites, primary tumor cells must first gain access to the circulation and later reenter the tissues. Both involve moving through tissues as well as the
endothelial basement membrane. The degradative action of metalloproteases on these structures is critical for the migration of tumor cells (reviewed in Mignatti, P. and Rifkin, D.B. (1993) Physiol. Rev. 71:161-95) . MMPs have been implicated in periodontal disease.
Inflammation of the periodontium leads to connective tissue degradation and eventually to tooth loss. Tissue degradation is largely mediated by neutrophils attracted to the* inflammatory site, and secretion of neutrophil MMPs is believed to play a major role in tissue destruction (reviewed in Sodek, J. and Overall, CM. (1992) Matrix Suppl 1, 352-62) .
Metalloproteinases participate in bone resorption process. Collagenase produced by osteoblast cells degrades collagen overlying the surface of the bone and affords osteoclasts access to underlying mineralized bone. The osteoclasts in turn utilize MMPs as well as other proteases in bone resorption. This bone catabolism affects the overall balance of deposition/resorption and resulting imbalance can lead to demineralization of the bone and osteoporosis (Everts, V. et al . (1992) J. Cell Physiol. 150:221-231: Vaes, G. et al . (1992) Matrix, Suppl . 1. 383-388) .
There is evidence for MMP involvement in corneal ulcer formation following alkali burns and bacterial inflammation ( entworth, J.S. et al . (1992) 3_3:2174-9; Burns, F.R. et al . (1992) Matrix, Suppl 1, 317-318) . Inhibition of MMPs may have a therapeutic effect in prevention of corneal ulceration resulting from a broad variety of insults.
The involvements of MMPs in this wide range of pathological conditions suggest that inhibitors of these enzymes would have broad therapeutic potential. As natural inhibitors of the MMPs, TIMPs should be medically useful for treatment of pathological conditions involving MMPs including but not limited to those discussed above.
BACKGROUND ART
There are two human TIMPs previously characterized on the sequence level, TIMP-1 (Docherty, A.J.P. et al . (1985) Nature 318:66-69 and TIMP-2 (Boone, T.C. et al . (1990) Proc.
Natl. Acad. Sci . 12=2800-2804; Stetler-Stevenson, .G. et al . (1990) J. Biol. Chem. 265:13933-38) . The proteins are classified in the TIMP family based on their structural similarity to each other as well as their mutual ability to inhibit metalloproteinases. Although both human TIMPs inhibit a range of metalloproteinases, their specificities do differ. TIMP-2 is a more effective inhibitor of both 72kDa gelatinase (MMP-2) and 92kDa gelatinase (MMP-9) , while TIMP-1 *is the better inhibitor of MMP-1, interstitial collagenase (Howard, E.W. et al . (1991) J. Biol. Chem. 266:13070-75) . In addition, there have been other reports of inhibitors of metalloproteinases (IMPs) with physical characteristics different from those of TIMP-1 or TIMP-2. In some cases these activities result from alternate forms of the known TIMPs. For instance, a recent report describes one IMP present in the conditioned media of a human bladder carcinoma to be a partially glycosylated form of TIMP-1 and another to be a partially processed/degraded form of TIMP-2 (Miyazaki, K. et al . (1993) J. Biol. Chem. 268:14387-93) . There are additional reports that describe sources and characteristics of IMP activity, but the gene products associated with these activities have not been delineated (Apodaca, G. et al . (1990) Cancer Research, 11:2322-29) • Thus, TIMP-1 and TIMP-2 are the only human TIMPs that have been fully characterized and cloned. It is impossible to know which of the activities described are due to novel members of the TIMP family or how many members of the TIMP family are encoded in the human genome.
Additional TIMPs have been cloned from other species including bovine TIMP-1 (Freudenstein et al . (1990) Biochem. Biophys. Res. Comm. 171:250-256) and TIMP-2 (Boone, T.C. et al . (1990) Proc. Natl. Acad. Sci. .87.:2800-2804) , urine TIMP-1 (Gewert, D.R. et al . (1987) EMBO J. 1:651-657) , rabbit TIMP-1 (Horowitz, S. et al. (1989) J. Biol. Chem. 264.7092-7095) and chicken TIMP-3 (Pavloff, N. et al . (1992) J. Biol. Chem. 267: 17321-6) . Chicken TIMP-3 is more closely homologous to TIMP-2 than TIMP-1 of other species. Cloned and fully characterized homologs of TIMP-1 and TIMP-2 from chickens have not been
reported. The protein of this invention is closely related to the TIMP family. Homology of this protein to human TIMP-1 and TIMP-2 is shown in Table 1. By sequence homology, the protein of this invention is clearly a new member of the human TIMP family. We therefore call this molecule human TIMP-3. Of the TIMP molecules reported so far, human TIMP-3 is most closely related to the chicken TIMP-3. The sequence alignment between these two molecules is shown in Table 1.
SUMMARY OF THE INVENTION
The subject invention provides a nucleotide sequence that uniquely identifies a novel human monocyte/macrophage derived protein. We designate this new gene "tissue inhibitor of metalloproteinases-3" or TIMP-3. Aspects of the subject invention include: purified TIMP-3; purified nucleotide sequences encoding all or a portion of said TIMP-3; recombinant- host cells or organisms for the production of TIMP-3; hybridization probes for detecting nucleotide sequences encoding TIMP-3; hybridization probes useful for regulating TIMP-3 gene transcription or translation; antibodies capable of specifically binding to TIMP-3; methods of detecting TIMP-3 with TIMP-3-specific antibodies, particularly in biological samples; methods of isolating recombinant or naturally-occurring TIMP-3 using TIMP-3- specific antibodies; methods of treating samples with TIMP-3 to inhibit proteolytic activity in the sample; pharmaceutical compositions comprising TIMP-3 in an acceptable excipient, and methods of treating diseases in which matrix metalloproteases play a role.
DESCRIPTION OF THE TABLE
Table 1 shows an amino acid homology analysis of chicken TIMP-3 and human TIMP-1, TIMP-2 and TIMP-3. The sequence of human TIMP-3 is also presented as SEQ ID NO: 2 of the Sequence Listing.
DESCRIPTION OF THE FIGURES
Figure 1 shows an amino acid content graph of human
TIMP - 1 .
Figure 2 shows an amino acid content graph of human TIMP-2.
Figure 3 shows an amino acid content graph of human TIMP-3.
Figure 4 shows an isoelectric point curve of human TIMP-1.
Figure 5 shows an isoelectric point curve of human TIMP-2. Figure 6 shows an isoelectric point curve of human TIMP-3.
Figure 7 shows a hydrophobicity profile of human TIMP-1.
Figure 8 shows a hydrophobicity profile of human TIMP-2.
Figure 9 shows a hydrophobicity profile of human TIMP-3. Figures 10 A-C show RNA "Northern" blots of polyadenylated RNA isolated from various human tissues using a TIMP-3 probe.
Figure 11 shows a Southern blot of human chromosomal DNA digested with various restriction enzymes, and hybridized with a TIMP-3 probe.
Figures 12 A and B show a Southern blot of Eco RI- digested chromosomal DNA taken a variety of mammalian somatic cell hybrids that has been hybridized with a TIMP-3 probe.
Figure 13 shows a "zoo" blot of Eco Rl-digested chromosomal DNA from a variety of mammalian sources that has been hybridized with a TIMP-3 probe.
DETAILED DESCRIPTION OF THE INVENTION Definitions As used herein the term "TIMP-3" refers to endogenously encoded, i.e., a naturally occurring, polypeptide expressed by human THP-1 cells activated with endotoxin having the amino acid sequence backbone described in SEQ ID NO: 2 in the Sequence Listing and to allelic variants, derivatives, fragments, or recombinant forms that retain the biological characteristics of the naturally occurring human TIMP-3, i.e., metalloproteinase inhibitory activity. The term "naturally occurring TIMP-3" refers to TIMP-3 with a primary amino acid
sequence that is the same as the primary amino acid sequence of a TIMP-3 produced by a non-genetically engineered human cell in vi tro or in vivo .
The term "TIMP-3 derivative" is defined to include polypeptides possessing TIMP-3 biological activity and/or TIMP-3 immunological activity. The terms "biological activity" (or "biological characteristics") of a protein refers to the structural or biochemical function of* the protein in the normal biological processes of the organism in which the protein naturally occurs. Examples of biological characteristics of TIMP-3 include both its structure and/or conformation, which can be determined by specific antigenicity or immunogenicity, and the ability of the TIMP-3 to mediate inflammatory responses by the regulation of metalloproteinases in vivo . The term "biological activity" of TIMP-3 includes the range of biological characteristics associated with the native form of TIMP-3.
By TIMP-3 "immunological activity," it is intended that a polypeptide with TIMP-3 immunological activity can specifically bind with antibodies specific for TIMP-3, or can, upon injection into appropriate animals (with suitable adjuvants) , be used to induce an immune response specific for TIMP-3. Unless indicated otherwise, the term "TIMP-3 derivative" means TIMP-3 derivatives with biological activity and TIMP-3 immunological activity (i.e. are immunologically cross-reactive with antibodies specific for TIMP-3) .
"Derivatives" of TIMP-3 with TIMP-3 biological activity may have amino acid sequences that consist of the amino acid sequence of the naturally occurring TIMP-3 protein or the amino acid sequence of naturally occurring TIMP-3 protein with minor variations. TIMP-3 derivatives also include polypeptides with the amino acid sequence of TIMP-3 with one or more amino acid substitutions. Preferably, these amino acid substitutions are the result of the substitution of one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine, i.e., conservative
amino acid replacements. Furthermore, TIMP-3 derivatives may include polypeptides with the amino acid sequence of naturally occurring TIMP-3, but possessing various minor amino acid deletions and/or insertions, typically in the range of about 1 to 5 amino acids, as well as one or more amino acid substitutions. Guidance in determining which TIMP-3 amino acid residues may be replaced or deleted without abolishing TIMP-3 biological activities of interest may be found by searching computer libraries of protein amino acid sequences for proteins that are homologous to a given tissue inhibitor of metalloproteinases and minimizing the number of amino acid sequence changes in regions of homology between TIMP-3 and homologous proteins, such as TIMP-1 or TIMP-2, detected by a computer homology search. Additionally, TIMP-3 amino acid residues that may be replaced or deleted without abolishing TIMP-3 biological activities of interest may be determined by systematically making insertions, deletions, or replacement of TIMP-3 amino acids (by recombinant DNA techniques) and assaying for the biological activities of interest. The TIMP-3 protein may or may not be post-translationally modified. A "Post-translational" modification includes processes such as proteolytic cleavage (including the action of signal peptidases) , glycosylation, lipidation, and the like. The nature of post-translational modification may vary in accordance with the type of cell in which TIMP-3 is produced. Although the TIMP-3 gene is transcribed by endotoxin activated THP-1 cells, the naturally occurring expression of TIMP-3 is not known to be limited to THP-1 cells or macrophages or monocytes. A "mutation" in a protein alters its primary structure (relative to the commonly occurring or specifically described protein) due to changes in the nucleotide sequence of the DNA which encodes the protein. These mutations include allelic variants. Mutational changes in the primary structure of a protein result from deletions, additions or substitutions. A "deletion" is defined as a change in a polypeptide sequence in which one or more internal amino acid residues are absent.
An "addition" is defined as a change in a polypeptide sequence which has resulted in one or more additional internal amino acid residues as compared to the wild type.
A "substitution" results from the replacement of one or more amino acid residues by other residues .
A protein "fragment" is a polypeptide consisting of a primary amino acid sequence which is identical to a portion of the primary sequence of the protein to which the polypeptide is related. A host cell "expresses" a gene or DNA when the gene or DNA is transcribed and the protein encoded by the transcribed RNA is produced by translation.
DETAILED DESCRIPTION OF THE INVENTION The present invention provides for nucleotide sequences uniquely identifying TIMP-3, nucleotide sequences encoding TIMP-3, and purified TIMP-3.
Nucleotide sequences encoding TIMP-3 have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization or PCR probes, use for chromosome and gene mapping, use in the recombinant production of TIMP-3, generation of anti-sense RNA, DNA or nucleotide analogues, and the like. The uses of oligonucleotides encoding TIMP-3 provided for in this application are exemplary of known techniques and are not intended to reflect any limitation on their use in any technique that would be known to the person of average skill in the art. Furthermore, the nucleotide sequences provided for in this application may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of polynucleotide sequences that are currently known to the person of average skill in the art, e.g., the triplet genetic code, specific base pair interactions, etc. ' • It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of TIMP-3-encoding nucleotide sequences, some bearing minimal nucleotide sequence homology to the nucleotide sequence of the
naturally occurring TIMP-3 gene, may be produced. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring TIMP-3 encoding nucleotide sequences and all such variations are to be considered as being specifically disclosed. Although nucleotide sequences of interest encoding TIMP-3 and TIMP-3 derivatives are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring TIMP-3 gene under stringent conditions, it may be advantageous to produce nucleotide sequences encoding TIMP-3 or TIMP-3 derivatives possessing a substantially different codon usage. Codons may be altered by chemical synthesis of the entire gene or relevant portions thereof, or by recombinant DNA methods including but not limited to site- directed mutagenesis (see generally, Ausubel, F.M. et al. (1989) in Current Protocols in Molecular Biology, John Wiley & Sons, and periodic updates thereof) . Codons can be selected to increase the rate at which expression of the protein or peptide occurs in a particular expression host organism in accordance with the frequency with which a particular codon is utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding TIMP-3 and/or a TIMP-3 derivative without altering the amino acid sequence include the production of RNA transcripts having more desirable properties, e.g., a greater half-life, than transcripts produced from the naturally occurring TIMP-3 encoding nucleotide sequence and the like.
Nucleotide sequences encoding TIMP-3 may be joined to a variety of other nucleotide sequences of interest by means of well established recombinant DNA techniques (see, for example, Sambrook et al . (1989) , Molecular Cloning: A Laboratory Manual, 2nd Ed.. Cold Spring Harbor) .
Interesting nucleotide sequences for joining to TIMP-3 sequences include an assortment of cloning vectors, e.g.,
plasmids, cosmids, phage derivatives, phagemids, and the like, that are known in the art . Vectors of interest include expression vectors, replication vectors, probe generation vectors, sequencing vectors, and the like. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease digestion sites, and selectable markers for the host cell.
Another aspect of the subject invention is to provide for TIMP-3-specific nucleic acid hybridization probes capable of hybridizing with naturally occurring nucleotide sequences encoding TIMP-3. Nucleic acid hybridization probes for the detection of TIMP-3 encoding nucleotide sequences should preferably contain at least 50% of the nucleotides from the sequence of a given TIMP-3 encoding nucleotide sequence. The hybridization probes of the subject invention may be derived from the nucleotide sequences of the Sequence Listing and the genomic sequences encoding TIMP-3 uniquely identified by the nucleotide sequences of the Sequence Listing. Hybridization probes may be labeled by a variety of reporter groups, including radionuclides such as 32P or 35S, or enzymatic labels such as alkaline phosphatase, coupled to the probe via avidin/biotin coupling systems, and the like.
An additional use for nucleic acid hybridization probes involves their use as primers for PCR, the polymerase chain reaction. The polymerase chain reaction is described in detail in U.S. Patents 4,965,188 and 4,683,195 and 4,800,195.
Probes for hybridization may be synthesized by both enzymatic and in vi tro techniques. Short hybridization probes are preferably synthesized by in vi tro methodology such as the use of commercially available DNA synthesizers like machines sold by Applied Biosystems. For example, nucleotide sequences of lengths greater than 10 base pairs may be produced by commercially available machines. Oligonucleotides produced by in vitro synthesis may be readily spliced together using generally known recombinant DNA techniques to produce a longer sequence of interest .
Other means of producing TIMP-3-specific hybridization probes include the cloning of nucleic acid sequences encoding TIMP-3 and TIMP-3 derivatives into vectors for the production of RNA probes . Such vectors are known in the art and are commercially available and may be used to synthesize RNA probes in vi tro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase, or the like, and the appropriate radioactively labeled nucleotides.
It is now possible to produce a DNA sequence, or portions thereof, encoding TIMP-3 and TIMP-3 derivatives entirely by synthetic chemistry, after which the gene can be inserted into any of the many available DNA vectors using reagents, vectors and cells that are known in the art at the time of the filing of this application. Synthetic chemistry may be used to reproduce the entire sequence of a TIMP-3 encoding gene, any portion thereof, or to introduce in mutations into the sequence.
The nucleotide sequence for TIMP-3 can be used to construct hybridization probes for mapping the TIMP-3 gene and for the genetic analysis of individuals with TIMP-3 genetic disorders, allelic variants or other genetic traits of interest. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosomes using well known genetic and/or chromosomal mapping techniques. These techniques include in si tu hybridization, linkage analysis against known chromosomal markers, hybridization screening with libraries or flow-sorted chromosomal preparations specific to known chromosomes, and the like. The technique of fluorescent in si tu hybridization of chromosome spreads has been described, among other places, in Verma et al . Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York (1988) . Fluorescent in si tu hybridization of chromosomal preparations and other physical chromosome mapping techniques, may be correlated with additional genetic map data. Examples of genetic map data can be found, for example, in Genetic Maps: Locus Maps of Complex Genomes, Book 5 : Human Maps, O'Brien, editor, Cold Spring Harbor Laboratory Press (1990) . Correlation between a
SUBSTITUTESHEET(RULE26.
physical chromosomal map may be of particular interest in detecting genetic diseases in affected individuals and potential carriers of genetic diseases. The nucleotide sequence of the subject invention may be used to detect differences in the sequence of genes that vary between normal individuals and affected individuals.
Nucleotide sequences encoding TIMP-3 may be used to produce purified TIMP-3 using well known methods of* recombinant DNA technology. Among the many publications that teach methods for the expression of genes after they have been isolated is Gene Expression Technology, Methods and Enzymology. Vol. 185, edited by Goeddel, Academic Press, San Diego, California (1990) . TIMP-3 may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from species either the same or different than the species from which the TIMP-3 encoding nucleotide sequences are naturally present, i.e., endogenous. Advantages of producing the TIMP-3 by recombinant DNA technology include obtaining highly enriched sources of the proteins for purification and the availability of simplified purification procedures.
Cells transformed with expression vectors encoding TIMP-3 may be cultured under conditions favoring expression of the TIMP-3 sequence and the recovery of the recombinantly produced protein from the cell culture. TIMP-3 produced by a recombinant cell may be secreted or may be contained intracellularly, depending on the particular genetic construction used. In general, it is more convenient to prepare recombinant proteins in secreted form. Purification steps will depend on the nature of the production and the particular TIMP-3 produced.
In addition to recombinant production, TIMP-3 fragments may be produced by direct peptide synthesis using solid-phase techniques. See Stewart et al . , Solid-Phase Peptide Synthesis (1969) , W. H. Freeman Co., San Francisco, and Merrifield, J. Am. Chem. Soc. 8≥:2149-2154 (1963) .
In vi tro polypeptide synthesis may be performed using manual techniques or by automation. Automated synthesis may
be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Foster City, California) following the instructions provided in the instruction manual supplied by the manufacturer. Antibodies specific for a TIMP-3 may be produced by using TIMP-3 for the induction of said TIMP-3-specific antibodies. By induction of antibodies it is intended not only the stimulation of an immune response by injection into animals, but analogous steps in the production of synthetic antibodies or other specific-binding molecules such as the screening of recombinant immunoglobulin libraries, Orlandi, R. et al . , (1989) PNAS USA 8.6:3833-3837 or Huse, W.D. et al . , (1989) Science 256 :1275-1281, or the in vi tro stimulation of lymphocyte populations. Current technology, e.g., Winter, G. and Milstein, C. (1989) Nature, 3_4_9:293-299, provides for a number of highly specific binding reagents based on the principles of antibody formation; these techniques may readily be adapted to produce molecules capable of specifically binding TIMP-3. TIMP-3 for use in the induction of antibodies of interest does not need to have biological activity; however, TIMP-3 for use in the induction of antibodies will necessarily have immunological activity. Polypeptides for use in the induction of TIMP-3-specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids, mimicking a portion of the amino acid sequence of TIMP-3, and may contain the entire amino acid sequence of naturally occurring TIMP-3 or a TIMP-3 derivative. An additional embodiment of the subject invention is the use of a composition comprising human TIMP-3, or derivatives thereof, as bioactive agents for the treatment of diseases including but not limited to: inflammation, arthritis, connective tissue disorders, periodontal disease, dermatological disorders, infection, ophthalmic disorders, corneal ulceration, orthopedic disorders, osteoporosis, autoimmune disease, and cancer. Compositions comprising TIMP- 3 or derivatives thereof may also find application as
ingredients or medicinal components of cosmetic or topical compositions.
When used in the therapeutic treatment of disease, an appropriate dosage of TIMP-3 or a TIMP-3 derivative may be determined by any of several well established methodologies. For instance, animal studies are commonly used to determine the maximal tolerable dose, or MTD, of bioactive agent per kilogram weight of the test subject. In general, at least one animal species tested is mammalian. Those skilled in the art regularly extrapolate doses for efficacy and avoiding toxicity to other species, including human. Before human studies of efficacy are undertaken, Phase I clinical studies in normal subjects help establish safe doses.
Additionally, the bioactive agent may be complexed with a variety of well established compounds or structures that, for instance, enhance the stability of the bioactive agent, or otherwise enhance its pharmacological properties (e.g., increase in vivo half-life, reduce toxicity, etc.) .
Where diagnostic, therapeutic or medicinal use of TIMP-3 or derivatives thereof is contemplated, the bioactive agent may be introduced in vivo by any of a number of established methods. For instance, the agent may be administered by inhalation; by subcutaneous (sub-q) ; intravenous (I.V.) , intraperitoneal (I.P.) , intramuscular (I.M.) injection; or as a topically applied agent (transdermal patch, ointments, creams, salves, eye drops, and the like) .
The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention .
EXAMPLES
I. CONSTRUCTION OF cDNA LIBRARIES
The human monocyte THP-1 cDNA library was custom constructed by Stratagene (Stratagene, 11099 M. Torrey Pines Rd., La Jolla, CA 92037) . Poly(A+)RNA (mRNA) was purified from THP-1 cells (cultured 48 hr with lOOnm TPA and 4 hr with lμg/ml LPS) . cDNA synthesis was primed separately "with both oligo dT and random hexamers and the two cDNA libraries were treated separately. Synthetic adaptor oligonucleotides were ligated onto cDNA ends enabling its insertion into Uni-ZAP™ vector system (Stratagene) , allowing high efficiency unidirectional (sense orientation) lambda library construction and the convenience of a plasmid system with blue/white color selection to detect clones with cDNA insertions. Finally, the two libraries were combined into a single library by mixing equal numbers of bacteriophage.
The THP-1 cDNA library can be screened with either DNA probes or antibody probes and the pBluescript® phagemid (Stratagene) can be rapidly excised in vivo . The phagemid allows the use of a plasmid system for: easy insert characterization, sequencing, site-directed mutagenesis, the creation of unidirectional deletions and expression of fusion proteins. The custom-constructed library phage particles-were infected into E. coli host strain XLl-Blue® (Stratagene) , which has a high transformation efficiency, increasing the probability of obtaining rare, under-represented clones in the cDNA library.
II. ISOLATION OF cDNA CLONES
The phagemid forms of individual cDNA clones were obtained by the in vivo excision process in which the host bacterial strain was coinfected with both the lambda library phage and an fl helper phage. Proteins derived from both the library-containing phage and the helper phage nicked the lambda DNA, initiated new DNA synthesis from defined sequences on the lambda target DNA and created a smaller, single stranded circular phagemid DNA molecule that included all DNA
sequences of the pBluescript® plasmid and the cDNA insert . The resulting phage containing the phagemid DNA were secreted from the cells, purified, and then used to re-infect fresh host cells, where the double stranded phagemid DNA was produced. Because the phagemid carries the gene for
/β-lactamase, the newly-transformed bacteria are selected on medium containing ampicillin.
Phagemid DNA was purified using the Magic Minipreps™ DNA Purification System (Promega catalogue #A7100. Promega Corp., 2800 Woods Hollow Rd. , Madison, WI 53711) . This small-scale process provides a simple and reliable method for lysing the bacterial cells and rapidly isolating purified phagemid DNA using a proprietary DNA-binding resin. The DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.
Phagemid DNA was also purified using the QIAwell-8 Plasmid Purification System from QIAGEN® DNA Purification System (QIAGEN Inc., 9259 Eton Ave. , Chatsworth, CA 91311) . This product line provides a convenient, rapid and reliable high-throughput method for lysing the bacterial cells and isolating highly purified phagemid DNA using QIAGEN anion-exchange resin particles with EMPORE™ membrane technology from 3M in a multiwell format. The DNA was eluted from the purification resin already prepared for DNA sequencing and other analytical manipulations.
III. SEQUENCING OF cDNA CLONES
The cDNA inserts from random isolates of the THP-1 library were sequenced in part. Methods for DNA sequencing are well known in the art. Conventional enzymatic methods employ DNA polymerase Klenow fragment, Sequenase™ or Taq polymerase to extend DNA chains from an oligonucleotide primer annealed to the DNA template of interest. Methods have been developed for the use of both single- and double-stranded templates. The chain termination reaction products are usually electrophoresed on urea-polyacrylamide gels and are detected either by autoradiography (for radionuclide-labelled precursors) or by fluorescence (for fluorescent-labelled
precursors) . Recent improvements in mechanized reaction preparation, sequencing and analysis using the fluorescent detection method have permitted expansion in the number of sequences that can be determined per day (such as the Applied Biosystems 373 DNA sequencer and Catalyst 800) .
IV. HOMOLOGY SEARCHING OF cDNA CLONE AND DEDUCED PROTEIN
Using the nucleotide sequences derived from the cDNA clones as query sequences (the sequences of the Sequence
Listing) , databases containing previously identified sequences are searched for areas of homology (similarity) . Such databases include Genbank and EMBL. Two homology search algorithms were used.
The first algorithm was originally developed by D.J.
Lipman and W.R. Pearson, "Rapid and Sensitive Protein Similarity Searches", (1985) Science, 227:1435. In this algorithm, the homologous regions are searched in a two step manner. In the first step, the highest homologous regions are determined by calculating a matching score using a homology score table. The parameter 'Ktup' is used in this step to establish the minimum window size to be shifted for comparing two sequences. Ktup also sets the number of bases that must match to extract the highest homologous region among the sequences. In this step, no insertions or deletions are applied and the homology is displayed as an initial (INIT) value.
In the second step, the homologous regions are aligned to obtain the highest matching score by inserting a gap in order to add a probable deleted portion. The matching score obtained in the first step is recalculated using the homology score Table and the insertion score Table to an optimized (OPT) value in the final output.
DNA homologies between two sequences can be examined graphically using the Harr method of constructing dot matrix homology plots (Needleman, S.B. and Wunsch, CO., (1970) J. Mol . Biol. .48.:443) . This method produces a two-dimensional
plot which can be useful in determining regions of homology versus regions of repetition.
The second algorithm was developed by Applied Biosystems Inc. and has been incorporated into the Inherit 670 Sequence Analysis System. In this algorithm, Pattern Specification Language (developed by TRW Inc.) is used to determine regions of homology. There are three parameters that determine how the sequence comparisons are run: window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database is searched for sequences containing regions of homology and the appropriate sequences are scored with an initial value. Subsequently, these homologous regions are examined using dot matrix homology plots to determine regions of homology versus regions of repetition. Smith-Waterman alignments were used to display the results of the homology search.
Following the search for homologous regions, the sequences from the cDNA clones were classified as to whether they are exact matches (regions of exact homology) , homologous human matches (regions of high similarity, but not exact matches) , homologous non-human matches (regions of high similarity present in species other than human) , or nonmatches (no significant regions of homology to previously identified nucleotide sequences) . Searches of the deduced proteins and peptides are done in a manner analogous to that done with the cDNA sequences. The sequence of the protein is used as a query sequence and compared to the previously identified sequences contained in a database such as Swiss/Prot or the NBRF Protein database to find homologous proteins. These proteins are initially scored for homology using a homology score Table (Orcutt, B.C. and Dayhoff, M.O. Scoring Matrices, PIR Report MAT - 0285 (February 1985)) resulting in an INIT score. The homologous regions are aligned to obtain the highest matching scores by inserting a gap which adds a probable deleted portion. The matching score is recalculated using the homology score Table and the insertion score Table resulting in an optimized (OPT) score. Even in the absence of knowledge of the proper reading
frame of an isolated sequence, the above-described protein homology search may be performed by searching all 3 reading frames .
Peptide and protein sequence homologies can also be ascertained using the Inherit 670 Sequence Analysis System in an analogous way to that used in DNA sequence homologies . Pattern Specification Language and parameter windows are used to search protein databases for sequences containing regions of homology which are scored with an initial value. Subsequent examination with a dot-matrix homology plot determines regions of homology versus regions of repetition.
V. IDENTIFICATION OF TIMP-3 CDNA
Using the methodology described above, Incyte template #12006 was found to be homologous to members of the TIMP family, a family of homologous proteins which are known to be inhibitors of the matrix metalloproteinases. When raw sequence data was analyzed for homology with the GENBANK database, the best match was found to be with GENBANK entry CHKHIMP3A, the entry for a chicken TIMP. Template #12006 was also found to be homologous to several other members of the TIMP family from a variety of species. The Document Hit scores for all homologies detected were low, identifying template #12006 as a homolog for the database entries rather than an exact match. The homology between human TIMP-3 and human TIMP-1 and TIMP-2 as well as chicken TIMP-3 is shown in Table 1.
The predicted isoelectric points for human TIMPs 1-3 were measured and these data are presented in Figures 4-6. The human TIMPs comprise the following number of charged amino acids, N- and C-termini, and isoelectric points:
5 Isoelectric Point [pi] 8.00 6.45 9.04
Other templates have been exact matches to previously known human TIMPs. Subsequently, two other template sequences 0 (#12417 and #12777) were identified which also showed homology to the TIMP family of protease inhibitors.
VI. ANTISENSE ANALYSIS
Knowledge of the correct, complete cDNA sequence of the 5 novel TIMP-3 gene will enable its use in antisense technology in the investigation of its gene function. Oligonucleotides, gene, or cDNA fragments encoding sequence corresponding to the antisense strand of the TIMP-3 gene can be used either in vi tro or in vivo to inhibit a specific gene function. By 0 treatment of cells or whole test animals with such antisense probes, the gene of interest can be effectively turned off. Frequently, the function of the genes of interest can be ascertained by observing cellular or organismic behavior (e.g. lethality, loss of differentiated function, changes in 5 mobility or morphology, changes in surface antigens) .
By the same methodology, the expression of a gene whose function it may be desirable to inhibit or turn-off may be manipulated. For example, a new gene whose function is
related to a human disorder can be treated therapeutically by administration (either orally or intravenously) of antisense DNA, RNA or nucleotide derivatives which hybridize to DNA to shut off transcription of the offending or diseased gene. Such technology is now well known in the art, and can be designed at various locations within the coded gene sequence. Similarly, such inhibition can be achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing. In addition to the gene itself, modifications of gene expression can be obtained by designing antisense probes to extragenic regions such as promoter regions, enhancer regions, or even to other genes which control or inhibit the synthesis of the gene of interest .
VII. EXPRESSION OF cDNA CLONES
Translation of cloned TIMP-3 cDNA into protein may be accomplished by subcloning the cDNA into an appropriate expression vehicle and subsequently into an appropriate expression host. In this particular case, the library cloning vector used for the generation of the THP-1 library includes provisions for direct expression of the included sequence in E. coli: upstream of the cloning site lies a promoter for /S-galactosidase, followed by the amino-terminal Met and subsequent 7 residues of /S-galactosidase. Immediately following this is an engineered bacteriophage promoter (useful for artificial priming and transcription) , and other included unique restriction sites, up to and including the Eco RI cloning site and subsequent cDNA insert . Since cDNA clone inserts are generated by an essentially random process, there is a one-in-three chance that the included cDNA will lie in the correct frame for proper translation, and that induction of the isolated bacterial strain with IPTG using standard methods will produce a fusion protein corresponding to the first seven residues of B-galactosidase, some 15 residues of "linker", and the peptide encoded within the cDNA. There is also a two in three chance the cDNA will lie in the wrong reading frame. If the cDNA is not in the proper reading frame, the proper reading frame can be obtained by deletion or
insertion of the appropriate bases by well known methods including in vi tro mutagenesis, nuclease digestion, or oligonucleotide linker inclusion, and used subsequently for bacterial expression studies as described. Oligonucleotide amplimers containing cloning sites as well as a segment of DNA sufficient to hybridize to stretches at both ends of the target cDNA (25 bases) can be synthesized chemically by standard methods . These primers can then used to amplify the desired gene segments by Polymerase Chain Reaction (PCR) . The resulting new gene segments can be digested with the corresponding restriction enzyme under standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments can be produced by digestion of the cDNA itself with appropriate restriction enzymes and filling in missing gene segments with chemically synthesized oligonucleotides. These segments of coding sequence can be ligated together and cloned into appropriate expression vectors which would allow recombinant production of the encoded sequence. Suitable expression systems for such chimeric molecules include but are not limited to mammalian cells such as CHO cells, fungi, such as yeast, insect cells and viruses, such as Baculovirus, and bacteria such as E. coli . For each of these cell systems, a useful expression vector may include a selectable phenotypic marker, e.g., an antibiotic resistance gene, such as β-lactamase, that would allow selection of recombinant clones; a second selectable marker to allow selection on the host cells containing the expression vector, such as neomycin phosphotransferase; replication origin to allow propagation in bacteria; a high level promoter driving a gene inserted into an insertion site, such as retroviral long terminal repeat (LTR) promoter/enhancers, the MMTV, SV40, or metallothionine promoter for CHO cells, the trp, lac, tac or T7 promoter for bacterial hosts, or the alpha factor or PGH promoters in yeast; transcription enhancers for the mammalian hosts, such as the RSV enhancer; and a polyadenylation site, AATAAA, if one does not exist within the cDNA sequence. Once homogeneous cultures of recombinant cells are obtained through standard
culture methods, large quantities of recombinantly produced TIMP-3 can be recovered and analyzed from the conditioned medium through standard chromatographic methods .
VIII. ISOLATION OF RECOMBINANTLY PRODUCED TIMP-3
TIMP-3 may be expressed recombinantly in such a way as to facilitate purification of the TIMP-3 protein. Such an approach involves expression of the TIMP-3 as a chineric protein with one or more additional polypeptide modules; these modules provide for a general method for purification of the chimeric proteins. The term "module" refers to a domain of a protein not naturally present on naturally occurring TIMP-3. Such purification facilitating modules include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification utilizing immobilized metals, protein A extensions that allow purification on immobilized immunoglobulin, and the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA) . The inclusion of a linker sequence (such as Factor XA or enterokinase) upstream of the TIMP-3-encoding sequence may be useful to facilitate subsequent cleavage of the intact TIMP-3 protein.
IX. PRODUCTION OF ANTI-TIMP-3 ANTIBODIES Two approaches are utilized to raise antibodies to TIMP-3 and both approaches can be used to generate either polyclonal or monoclonal antibodies. In one approach, a denatured protein from the reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein can be used to immunize mice or rabbits using standard protocols; about 100 micrograms are adequate for immunization of a mouse, while up to 1 mg might be used to immunize rabbit. For screening mouse hybridomas, the denatured protein can be radioiodinated and used to screen murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg would be sufficient for labeling and screening of several thousand clones.
In the second approach, the amino acid sequence of TIMP-3, as deduced from the TIMP-3-cDNA, is analyzed to determine regions of high immunogenicity. The corresponding polypeptides are synthesized and are used in suitable immunization protocols to raise antibodies. Analysis to select appropriate epitopes is described by, for example, Ausubel, F.M. et al., in Current Protocols in Molecular Biology, John Wiley __ Sons, Vol. 2, Sec. IV, pp 11.14.1, 1989. The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and intervening regions of the polypeptide, which are likely to be exposed to the external environment when the protein is in its natural conformation (usually the most hydrophilic regions of the molecule) . Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH, Sigma) by reaction with M-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (See Ausubel et al . , supra at pp 11.15.1) . If necessary, a cysteine may be introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with antisera, washing and reacting with radioiodinated affinity purified specific goat anti-rabbit IgG.
Hybridomas may be also be prepared and screened using standard techniques. Hybridomas of interest are detected by screening with radioiodinated TIMP-3 to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST, Becton-Dickinson, Palo Alto, CA) , are coated with affinity purified specific rabbit-anti-mouse (or suitable' anti-species Ig) antibodies at 10 mg/ml. The coated wells are blocked with 1% BSA, washed and exposed to supernatants from hybridomas. After incubation the wells are exposed to radiolabeled TIMP-3, 1 mg/ml. Clones producing antibodies will bind a quantity of
radioactivity which is detectable above background. Such clones are expanded and subjected to 2 cycles of cloning at 0.3 cells/well. Cloned hybridomas are injected into pristine treated mice to produce ascites, and monoclonal antibody is 5 purified from the ascitic fluid by affinity chromatography on Protein A.
X. SCREENING OF ANTI-TIMP-3 ANTIBODIES AGAINST HUMAN MONOCYTE/MACROPHAGE CELLS
Some TIMP-3 specific antibodies may be useful for the
10 diagnosis of prepathologic conditions, as well as the diagnosis of chronic and acute diseases that are characterized by abnormalities in the amount or distribution of TIMP-3. A variety of protocols for immunoassays, using either polyclonal
15 or monoclonal antibodies specific for TIMP-3, are known in the art, e.g., competitive binding assays and immunoradiometric assays . Immunoassays typically involve the formation of complexes between TIMP-3 and a TIMP-3-specific antibody (or similar TIMP-3-specific molecule) and the measurement of
20 complex formation. A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on TIMP-3 is preferred, but a competitive binding assay may also be employed. These assays are described, among other places, in Maddox, D.E. et al., J. Exp. Med. (1983)
25 158 :1211.
Immunoassay procedures are utilized to measure several major parameters in immunopathologic and prepathologic conditions which are characterized by TIMP-3 abnormalities, e.g., the increased or decreased production of TIMP-3 by
30 monocytes/macrophages, the aberrant production of TIMP-3 by cells other than human monocytes/macrophages, and the change in intracellular or extracellular distribution of TIMP-3 during the genesis of disease. In order to determine the normal distribution of TIMP-3 in monocytes, peripheral blood
35 mononuclear cells from normal individuals are prepared using Ficoll-Paque (Pharmacia) and analyzed as described by Marra et al . (1991) J. Immun. 148:532-537. The quantity of TIMP-3 in monocyte/macrophages may be determined by performing
immunoassays on freeze-thawed detergent extracts of cell suspensions enriched for monocyte/macrophages and comparing the slope of the binding curves to comparable binding curves generated by the purified protein.
XI. PURIFICATION OF NATIVE TIMP-3 USING ANTI-TIMP-3 ANTIBODIES
Native or recombinant TIMP-3 may be purified by immunoaffinity chromatography using TIMP-3-specific antibodies. In general, an immunoaffinity column is constructed by covalently coupling the anti-TIMP-3 antibody to an activated chromatographic resin.
Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, NJ) . Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified Ig is covalently attached to a chromatographic resin, for example CnBr activated Sepharose (Pharmacia LKB Biotechnology, Piscataway, NJ) . The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturers instructions .
Such an immunoaffinity column is utilized in the purification of TIMP-3 by preparing a fraction from cells containing TIMP-3 in a soluble form. This preparation may be derived by solubilization of the whole cell, e.g., by the addition of detergent, or by the similar solubilization of a subcellular fraction by well known methods, e.g., differential centrifugation. Alternatively, the soluble TIMP-3 may be secreted into the medium conditioned by growth of cells that express TIMP-3 in useful quantity.
A soluble TIMP-3 containing preparation is passed over the immunoaffinity column and the column is washed under conditions that allow the preferential absorbance of TIMP-3, for example, in high ionic strength buffers in the presence of detergent. The column is then eluted under conditions that
disrupt antibody/TIMP-3 binding, e.g., a buffer of pH 2-3 or the presence of high concentration of a chaotrope, e.g. urea or the thiocyanate ion.
XII. TIMP-3 FULL LENGTH CLONING AND CHARACTERIZATION
Three clones, 12006, 12417, and 12777 were discovered to contain TIMP-3 encoding sequence, and overlapped each other, implying discrete reverse transcriptase termination*sites. The clone extending furthest in the 5' -direction, 12006, initiated 324 bases upstream from the stop codon, and therefore was incomplete at the 5' end. The cDNA insert from clone 12006 was excised from the clone DNA via restriction enzyme digestion, and was used as a hybridization probe against the THP-1 library. Hybridized under normal stringency conditions, 19 clones were detected by autoradiography. All 19 clones were selected for further analysis as follows: Each clone and its 10-20 neighboring clones (picking the correct individual at high density would be very difficult) were removed from the agar plate and soaked in 1 ml of SM buffer (Sambrook, J. et al . (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor) . The DNA recovered was used as a target for PCR amplification with two specific amplimers: One amplimer corresponded to DNA sequence (SEQ ID NO: 3) of the T3 promoter (5'-AGC TCG AAA TTA ACC CTC ACT AAAG-3') in the cloning vector immediately upstream from the insert itself. The other was complementary to bases 12 through 38 of the clone 12006 sequence (5'-TAC ATC CAT ACG GAA GTT TCC GAG AGT-3'; SEQ ID NO: 4) . When the PCR products were analyzed by gel electrophoresis, the lengths of the sequences between the clone 12006 sequence and the start of the clone insert could be ascertained. The clone (IMP1) showing the longest PCR product (about 600 nucleotides) was purified to homogeneity, excised, amplified, extracted and sequenced by standard methods. The sequence included all of the putative amino acid coding regions for TIMP-3, and is shown as SEQ ID NO: 1 in the Sequence Listing.
XIII. NORTHERN AND SOUTHERN BLOTS
A probe was prepared by labeling insert from clone 12006 to a specific activity of approximately 1 x 109 cpm/μg, using α_32 p 3CTP (3000Ci/mmol, Amersham, Arlington Heights, IL) with a commercially available random primer labeling kit (Promega Corp., 2800 Woods Hollow Rd. , Madison, WI 53711) . Multi- Tissue Northern (MTN) blots and the genomic Southern blot (GENO-BLOT™) were obtained from Clontech, Inc., Palt. Alto, CA. These and the chromosomal localization blot (BIOSMAP™; BIOS Inc., New Haven, CT) were probed under standard high stringency conditions (hybridization: 5xSSPE, lOx Denhardt's, 0.1 mg/ml herring sperm DNA, 50% formamide, 2% SDS, 42°C; wash: 60°C, 0.2xSSC, 0.1% SDS) . All northern and Southern ' exposures used Kodak XAR-2 film with 2 L-PLUS intensifying screens (Fisher Biotech Inc., Pittsburgh, PA) at -70°C.
Tissue-specific transcription of TIMP-3 was examined by RNA blot analysis using 3 ug poly A+ RNA per lane. A PCR- generated TIMP-3 clone insert was used as the hybridization probe. Figures 10 A and 10 B contain normal adult tissues; Fig. 10 C contains human fetal tissues. The lanes correspond to spleen (1) , thymus (2) , prostate (3) , testis (4) , ovary (5) , small intestine (6) , colon (7) , peripheral blood leukocyte (8) , heart (9) , brain (10) , placenta (11) , lung (12) , liver (13) , skeletal muscle (14) , kidney (15) , pancreas (16) , fetal heart (17) , fetal brain (18) , fetal lung (19) , fetal liver (20) , and fetal kidney (21) . Molecular weight standards are shown along the left side of the blot.
Transcripts of 5.0, 2.6, and 2.4 kB were detected in all tissues examined and the 5.0 kB band represented at least 90% of the hybridization signal in most tissues. The ratio between the three bands seemed relatively invariant, except in the placental sample, where the relative levels of the 2.6 and 2.4 kB bands were much greater. The strongest hybridization signals were found in spleen, prostate, ovary, small intestine, heart, placenta, lung, and kidney. Significantly less TIMP-3 mRNA was detectable in colon, peripheral blood leukocytes, brain, liver, and pancreas although all three bands were clearly present. In general, the profile was
similar for fetal tissues; however, both fetal heart and liver contained increased levels of TIMP-3 mRNA relative to adult tissue. When the same filters were stripped and reprobed with actin cDNA, similar mRNA levels were detected in all 21 tissue 5 samples.
In Figure 11, TIMP-3 cDNA was used as a hybridization probe against blots of human chromosomal DNA digested with Eco RI (lane 2) , Hind III (lane 3) , Bam HI (lane 4) , Ps"t I (lane 5) , and Bgl II (lane 6) . Molecular weight standards are shown
10 along the left side of the blot. The signal pattern indicates that TIMP-3 mRNA originates from a very small number of genes, most likely a single gene. The DNA hybridization patterns present no evidence that TIMP-3 is a member of a multigene family or even closely related to other genes. In Figure 12,
15 the TIMP-3 probe was hybridized to a blot of EcoRI-digested chromosomal DNA from 20 mouse/human and hamster/human somatic cell hybrids. Such blots are often useful for assigning genes to individual human chromosomes. Included are hamster DNA (lanes 1 and 15) , human DNA (lane 2 and 16) , mouse DNA (lane
20 13) , molecular weight markers (lanes 14 and 28) , and hybrids (lanes 3-11, 17-27) . Lane 8 represents chromosomes 1, 5, 12, 14,19, 21, and 22; lane 17, chromosomes 4, 5, 8, 22, X; lane 27, chromosomes 1, 5, 13, 19, 21, and 22. The 2.4 kB hybridization signals that correspond to the human gene were
25 detected in lanes 8, 17, and 27. This pattern is consistent only with localization on chromosome 5 or 22. Since no signal was detected in several other lanes containing the DNA of chromosome 5, TIMP-3 could be localized to chromosome 22. In Figure 13 a "zoo" blot (ZOO-BLOT™; Clontech, Inc.,
30 Palo Alto, CA) was probed with TIMP-3 cDNA under medium stringency conditions (as above except hybridization: 37°C; wash: lxSSC at 60°C) . The "zoo" blot contains EcoRI-digested chromosomal DNA from various species; human (lane 2) , rhesus monkey (lane 3) , rat (lane 4) , mouse (lane 5) , dog (lane 6) ,
35 cow (lane 7) , rabbit (lane 8) , chicken (lane 9) and
Saccharomyces cerevisiae; and it is used to determine the degree of conservation of the primary nucleotide sequence. Lane 1 contained molecular weight standards.
Signals of similar intensity and size were seen in lanes corresponding to human, monkey, dog, and cow. A distinct band of smaller size was visible in mouse DNA (lane 5) . No discrete bands could be discerned in the lanes corresponding to rat, rabbit, chicken or yeast DNA.
XIV. CONSTRUCTION OF THE EXPRESSION VECTOR
The full length cDNA for TIMP-3 including the native leader sequence was cloned into pCEP-4 (Invitrogen, San Diego, CA) using standard PCR techniques. pCEP-4 was introduced into competent E. coli strain DH5-c_ using standard heat-shock procedures. Amplified plasmid DNA was isolated, purified using the Qiagen® DNA Purification System (Qiagen, Chatsworth, CA 91311) , and used to transfect appropriate host cells such as Chinese Hamster ovary (CHO) , human 293 cells, Sf9 insect cells, or yeast, _____ cerevisiae, cells.
XV. EXPRESSION OF TIMP-3 IN 293-EBNA HOST CELLS
Host cells, 293-EBNA (Invitrogen, San Diego, CA) were transformed with the expression plasmid containing the TIMP-3 gene by lipofection (Gibco BRL, Grand Island, NY) according to standard protocol . Cells harboring plasmids were selected in REM (JRH Biosciences, Woodland, CA) or other similar basal medium such as DMEM/F12 (Gibco BRL) , 10% calf serum, and 2 mM L-glutamine supplemented with 250 μg/ml geneticin (Gibco BRL) and 400 μg/ml hygromycin B (Calbiochem, La Jolla, CA) . Transformed cell numbers were increased in the same selective medium in T-flasks (Costar, Cambridge, MA) and 500 ml spinner flasks (Corning, Corning, NY) . The protein, TIMP-3, was secreted from cells grown in modified 3L Bellco spinner flasks (Bellco, Vineland, NJ) . Cells were harvested from the conditioned medium by centrifugation.
XVI. TIMP-3 ZYMOGRAPHY Because chicken TIMP-3 is known to bind to extracellular matrix (ECM) , human TIMP-3 was tested for its ability to do the same. ECM was extracted from the surface of culture vessels upon which THP-1 cells had grown and also from the
outer membrane of THP-1 suspension culture cells. Aliquots of conditioned media, previously discussed above, and ECM from both vessels and suspension culture cells were electrophoresed to separate their various proteins. The resulting gel was soaked in collagen and subsequently digested with collagenase. The bands which were evident on the resulting zymogram are those of peptides that inhibit collagenase. TIMP-3 presence, size, and activity were verified using this reverse zymography process (Tyagi, S.C. et al . (1993) Mol . Cell. Biol. !26_:49-59) .
XVII. PRODUCTION OF ANTIBODIES TO TIMP-3 PROTEIN
Antibodies were produced against peptides from two different hydrophilic regions of TIMP-3. These peptides were synthesized on an Applied Biosystems Peptide Synthesizer model 431A using Fmoc chemistry as specified by the manufacturer. The first synthetic peptide covered TIMP-3 amino acids 20 to 33, or RAKWGKKLVKEG (SEQ ID NO:5) . The second synthetic peptide covered TIMP-3 amino acids 172-187, or YRGWAPPDKSIINATD (SEQ ID NO:6) . The synthetic peptides, TIMP- 3/20-33 and TIMP-3/172-187, were conjugated to the carrier protein, keyhole limpet hemocyanin (KLH) using the Pierce Imject® Activated Immunogen Conjugation Kit. The KLH- conjugates were injected into female New Zealand white rabbits. Two booster inoculations were given at two and four weeks after the primary injection. Antisera were collected and titered against BSA-TIMP-3 conjugates using standard ELISA protocol. Both TIMP-3 antisera preparations had titers of 1:8000. All publications and patents mentioned in the above specification are herein incorporated by reference. The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.
25
SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: Incyte Pharmaceuticals, Inc.
3330 Hillview Avenue Palo Alto, California 94304 United States of America
(ii) TITLE OF INVENTION: Novel Human Monocyte/Macrophage- Derived Metalloproteinase, Its Production and Uses
(iii) NUMBER OF SEQUENCES: 3
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036-2711
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy Disk
(B) COMPUTER: IBM PC Compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: MS-DOS/Wordperfect 5.1
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: PCT To be assigned
(B) FILING DATE: 07-OCT-1994
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/133,956
(B) FILING DATE: 07-OCT-1993
ATTORNEY/AGENT INFORMATION:
(A) NAME: Albert P. Halluin
(B) REGISTRATION NUMBER: 25,227
(C) REFERENCE/DOCKET NUMBER: 8135-009-228
(viii) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415-854-3660
(B) TELEFAX: 415-854-3694
(C) TELEX: 66141 PENNIE
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1285 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(vii) IMMEDIATE SOURCE:
(B) CLONE: T-012006
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
GCGGCGGGCG CTCAGACGGC TTCTCCTCCT CCTCTTGCTC CTCCAGCTCC TGCTCCTTCG 60
CCGGGAGGCC GCCCGCCGAG TCCTGCGCCA GGCCGAGGCA GCCTCGCTGG CCCCATCCCG 120
TCCCGCCGGG CACTCGGAGG GCAGCGCGCC GGAGGNCAAG GTTGCCCCGC ACGGCCCGGC - 180
GGGCGAGCGA GCTCGGGCTG CAGCAGCCCC GCCGGNNNNC GCACGGCAAC TTTGGAGAGG 240
CGAGCAGCAGC CCCGGCAGC GGCGGCAGCA GCGGCA ATG ACC CCT TGG CTC GGG 294
Met Thr Pro Trp Leu Gly -20
CTC ATC GTG CTC CTG GGC AGC TGG AGC CTG GGG GAC TGG GGC GCC GAG * 342 Leu lie Val Leu Leu Gly Ser Trp Ser Leu Gly Asp Trp Gly Ala Glu -15 -10 -5
GCG TGC ACA TGC TCG CCC AGC CAC CCC CAG GAC GCC TTC TGC AAC TCC 390 Ala Cys Thr Cys Ser Pro Ser His Pro Gin Asp Ala Phe Cys Asn Ser 1 5 10 15
GAC ATC GTG ATC CGG GCC AAG GTG GTG GGG AAG AAG CTG GTA AAG GAG 438 Asp lie Val lie Arg Ala Lys Val Val Gly Lys Lys Leu Val Lys Glu 20 25 30
GGG CCC TTC GGC ACG CTG GTC TAC ACC ATC AAG CAG ATG AAG ATG TAC 486 Gly Pro Phe Gly Thr Leu Val Tyr Thr lie Lys Gin Met Lys Met Tyr 35 40 45
CGA GGC TTC ACC AAG ATG CCC CAT GTG CAG TAC ATC CAC ACG GAA GCT 534 Arg Gly Phe Thr Lys Met Pro His Val Gin Tyr lie His Thr Glu Ala 50 55 60
TCC GAG AGT CTC TGT GGC CTT AAG CTG GAG GTC AAC AAG TAC CAG TAC 582 Ser Glu Ser Leu Cys Gly Leu Lys Leu Glu Val Asn Lys Tyr Gin Tyr 65 70 75
CTG CTG ACA GGT CGC GTC TAT GAT GGC AAG ATG TAC ACG GGG CTG TGC 630 Leu Leu Thr Gly Arg Val Tyr Asp Gly Lys Met Tyr Thr Gly Leu Cys 80 85 90 95
AAC TTC GTG GAG AGG TGG GAC CAG CTC ACC CTC TCC CAG CGC AAG GGG 678 Asn Phe Val Glu Arg Trp Asp Gin Leu Thr Leu Ser Gin Arg Lys Gly 100 105 110
CTG AAC TAT CGG TAT CAC CTG GGT TGT AAC TGC AAG ATC AAG TCC TGC 726 Leu Asn Tyr Arg Tyr His Leu Gly Cys Asn Cys Lys lie Lys Ser Cys 115 120 125
TAC TAC CTG CCT TGC TTT GTG ACT TCC AAG AAC GAG TGT CTC TGG ACC 774 Tyr Tyr Leu Pro Cys Phe Val Thr Ser Lys Asn Glu Cys Leu Trp Thr 130 135 140
GAC ATG CTC TCC AAT TTC GGT TAC CCT GGC TAC CAG TCC AAA CAC TAC 822 Asp Met Leu Ser Asn Phe Gly Tyr Pro Gly Tyr Gin Ser Lys His Tyr 145 150 155
GCC TGC ATC CGG CAG AAG GGC GGC TAC TGC AGC TGG TAC CGA GGA TGG 870 Ala Cys lie Arg Gin Lys Gly Gly Tyr Cys Ser Trp Tyr Arg Gly Trp 160 165 170 175
GCC CCC CCG GAT AAA AGC ATC ATC AAT GCC ACA GAC CCC TGA GCGCCAGAC 921 Ala Pro Pro Asp Lys Ser lie He Asn Ala Thr Asp Pro *** 180 185
CCTGCCCCAC CTCACTTCCC TCCCTTCCCG CTGAGCTTCC CTTGGACACT AACTCTTCCC 981
AGATGATGAC AATGAAATTA GTGCCTGTTT TCTTGCAAAT TTAGCACTTG GAACATTTAA 1041
AGAAAGGTCT ATGCTGTCAT ATGGGGTTTA TTGGGAACTA TCCTCCTGGC CCCACCCTGC '1101
CCCTTCTTTT TGGTTTTGAC ATCATTCATT TCCACCTGGG AATTTCTGGT GCCATGCCAG 1161
AAAGAATGAG GAACCTGTAT TCCTCTTCTT CGTGATAATA TAATCTCTAT TTTTTTAGGA 1221
AAACAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1281
AAAA * 1285
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Chemically Synthesized Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: AGCTCGAAAT TAACCCTCAC TAAAG 25
(2) INFORMATION FOR SEQ ID NO:3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: Chemically Synthesized Oligonucleotide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: TACATCCATA CGGAAGTTTC CGAGAGT 27
Claims
1. A recombinant DNA molecule encoding TIMP-3.
2. An expression vector comprising the DNA of Claim
1
3. A host cell transformed with the expression vector of claim 2.
4. A method for production of TIMP-3, said method comprising the steps: a) culturing the host cells of claim 3 under conditions appropriate for expression of TIMP-3 and, b) recovering said TIMP-3 from the cell culture.
5. An antisense DNA molecule of Claim 1.
6. A purified polypeptide comprising amino acid sequence encoded by the nucleotide sequence of the sequence listing.
7. An antibody to the purified polypeptide of Claim 6-
8. A method of treating a disease comprising administering to an individual suffering from that disease a pharmaceutical composition comprising TIMP-3 in a pharmaceutically acceptable excipient.
9. A method of claim 8 wherein the disease is cancer.
10. A method of claim 8 wherein the disease is arthritis.
11. A method of claim 8 wherein the disease is periodontal disease.
12. A method of claim 8 wherein the disease is osteoporosis.
13. A method of claim 8 wherein the disease is corneal ulceration.
14. A diagnostic test using a polynucleotide probe with sequence corresponding to all or part of the recombinant DNA molecule of Claim 1 to assess inflammatory conditions.
15. A diagnostic test using the antibody of Claim 7 to assess inflammatory conditions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79773/94A AU7977394A (en) | 1993-10-07 | 1994-10-07 | Human monocyte/macrophage derived metalloproteinase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13395693A | 1993-10-07 | 1993-10-07 | |
US133,956 | 1993-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995009913A1 WO1995009913A1 (en) | 1995-04-13 |
WO1995009913A9 true WO1995009913A9 (en) | 1995-06-15 |
Family
ID=22461085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011599 WO1995009913A1 (en) | 1993-10-07 | 1994-10-07 | Human monocyte/macrophage derived metalloproteinase inhibitor |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7977394A (en) |
WO (1) | WO1995009913A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE403714T1 (en) | 1996-11-06 | 2008-08-15 | Univ California | TUMOR NECROSIS FACTOR RECEPTOR SEPARATING ENZYME, PREPARATIONS AND USES THEREOF |
US6709858B1 (en) | 1997-11-03 | 2004-03-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
US7098191B2 (en) | 1997-11-03 | 2006-08-29 | The Arizona Board Of Reagents | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
AU1101501A (en) * | 1999-10-27 | 2001-05-08 | K-Quay Enterprises, Llc | Methods and compositions for treatment of keratoconus using protease inhibitors |
MX2012001283A (en) * | 2009-07-31 | 2012-06-12 | Amgen Inc | Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods. |
CN106255694A (en) * | 2014-04-28 | 2016-12-21 | Jw制药公司 | Novel donipenem crystal and preparation method thereof |
-
1994
- 1994-10-07 WO PCT/US1994/011599 patent/WO1995009913A1/en active Application Filing
- 1994-10-07 AU AU79773/94A patent/AU7977394A/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5602102A (en) | Dipeptidyl peptidase-I inhibitors and uses thereof | |
AU711113B2 (en) | Novel serpin derived from human hypothalamus | |
JP2001525666A (en) | Human serine protease precursor | |
CA2139127A1 (en) | Compositions for the inhibition of protein hormone formation and uses thereof | |
US6599706B1 (en) | Recombinant PR-3 and assays employing the same | |
US5808001A (en) | Human ice homolog antibodies and compositions thereof | |
WO1995009913A9 (en) | Human monocyte/macrophage derived metalloproteinase inhibitor | |
WO1995009913A1 (en) | Human monocyte/macrophage derived metalloproteinase inhibitor | |
US5637462A (en) | Cathepsin C homolog | |
EP1133563A2 (en) | Methods and molecules relating to cd39-like polypeptides | |
NZ310749A (en) | The rasp-1 gene which is up-regulated in regenerating liver | |
US5998378A (en) | Compositions for the inhibition of TNF hormone formation and uses thereof | |
CA2214995A1 (en) | Hyaluronan receptor expressed in human umbilical vein endothelial cells | |
US5500344A (en) | Serine protease and uses thereof | |
US7195926B1 (en) | Antibodies to a cathepsin C homolog | |
US6586222B1 (en) | Recombinant PR-3 and compositions thereof | |
AU687751C (en) | Compositions for the inhibition of protein hormone formation and uses therof | |
MXPA97009270A (en) | Homologo de enzima conversion de interleucina-1 hum | |
EP0833908A1 (en) | Human homolog of the mouse rab18 gene | |
CA2142203A1 (en) | Basophil granule proteins | |
CA2236914A1 (en) | Interleukin-1.beta. converting enzyme like cysteine protease | |
MXPA97008030A (en) | New captecin homologo |